[
  {
    "drugName": "Olumiant",
    "setId": "866e9f35-9035-4581-a4b1-75a621ab55cf",
    "slug": "olumiant-866e9f3",
    "labeler": "Eli Lilly and Company",
    "label": {
      "boxedWarning": "WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS\nWARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS\nSee full prescribing information for complete boxed warning.\nSee full prescribing information for complete boxed warning.\nIncreased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2)Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)\nIncreased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)\nIncreased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)\nHigher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2)\nHigher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2)\nMalignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)\nMalignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)\nHigher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)\nHigher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)\nThrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)\nThrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)",
      "genericName": "baricitinib",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20241113",
      "title": "Olumiant",
      "indicationsAndUsage": "1.1 Rheumatoid Arthritis\n1.1 Rheumatoid Arthritis\nOLUMIANT (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.\nOLUMIANT (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.\nLimitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.\nLimitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.\n1.2 Coronavirus Disease 2019 (COVID-19)\n1.2 Coronavirus Disease 2019 (COVID-19)\nOLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\nOLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\n1.3 Alopecia Areata\n1.3 Alopecia Areata\nOLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.\nOLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.\nLimitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.\nLimitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.",
      "dosageAndAdministration": "2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation\n2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation\nPrior to OLUMIANT treatment initiation, consider performing the following evaluations:\nPrior to OLUMIANT treatment initiation, consider performing the following evaluations:\nActive and latent tuberculosis (TB) infection evaluation. OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with rheumatoid arthritis or alopecia areata, consider treatment for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].\nViral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)].\nComplete blood count. Assess baseline values and verify whether treatment can be initiated:\nIn patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/l, absolute neutrophil count (ANC) <1000 cells/l, or hemoglobin level <8 g/dL.\nIn patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/l or if the ANC is <500 cells/l.\nMonitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nBaseline hepatic and renal function. Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nActive and latent tuberculosis (TB) infection evaluation. OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with rheumatoid arthritis or alopecia areata, consider treatment for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].\nActive and latent tuberculosis (TB) infection evaluation. OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with rheumatoid arthritis or alopecia areata, consider treatment for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].\nViral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)].\nViral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)].\nComplete blood count. Assess baseline values and verify whether treatment can be initiated:\nIn patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/l, absolute neutrophil count (ANC) <1000 cells/l, or hemoglobin level <8 g/dL.\nIn patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/l or if the ANC is <500 cells/l.\nMonitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nComplete blood count. Assess baseline values and verify whether treatment can be initiated:\nIn patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/l, absolute neutrophil count (ANC) <1000 cells/l, or hemoglobin level <8 g/dL.\nIn patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/l or if the ANC is <500 cells/l.\nIn patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/l, absolute neutrophil count (ANC) <1000 cells/l, or hemoglobin level <8 g/dL.\nIn patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/l, absolute neutrophil count (ANC) <1000 cells/l, or hemoglobin level <8 g/dL.\nIn patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/l or if the ANC is <500 cells/l.\nIn patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/l or if the ANC is <500 cells/l.\nMonitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nMonitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nBaseline hepatic and renal function. Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nBaseline hepatic and renal function. Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\nIn patients with rheumatoid arthritis or alopecia areata, update immunizations in agreement with current immunization guidelines [see Warnings and Precautions (5.9)].\nIn patients with rheumatoid arthritis or alopecia areata, update immunizations in agreement with current immunization guidelines [see Warnings and Precautions (5.9)].\n2.2 Dosage Recommendations in Rheumatoid Arthritis\n2.2 Dosage Recommendations in Rheumatoid Arthritis\nThe recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food [see Clinical Pharmacology (12.3)]. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)]. OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.\nThe recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food [see Clinical Pharmacology (12.3)]. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)]. OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.\n2.3 Dosage Recommendations in COVID-19\n2.3 Dosage Recommendations in COVID-19\nThe recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)].\nThe recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)].\n2.4 Dosage Recommendations in Alopecia Areata\n2.4 Dosage Recommendations in Alopecia Areata\nThe recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.\nThe recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.\nFor patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food.\nFor patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food.\nOnce patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.\nOnce patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.\n2.5 Dosage Modifications Due to Infections, Cytopenias and Anemia\n2.5 Dosage Modifications Due to Infections, Cytopenias and Anemia\nRheumatoid Arthritis and Alopecia Areata\nRheumatoid Arthritis and Alopecia Areata\nAvoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection, hold treatment with OLUMIANT until the infection is controlled [see Warnings and Precautions (5.1)].\nDosage modifications for patients with rheumatoid arthritis or alopecia areata and cytopenias or anemia are described in Table 1.\nAvoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection, hold treatment with OLUMIANT until the infection is controlled [see Warnings and Precautions (5.1)].\nAvoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection, hold treatment with OLUMIANT until the infection is controlled [see Warnings and Precautions (5.1)].\nDosage modifications for patients with rheumatoid arthritis or alopecia areata and cytopenias or anemia are described in Table 1.\nDosage modifications for patients with rheumatoid arthritis or alopecia areata and cytopenias or anemia are described in Table 1.\nTable 1: Dosage Modifications for Cytopenias and Anemia in Patients with Rheumatoid Arthritis or Alopecia Areata\nLaboratory Analyte\nLaboratory Analyte Value\nRecommendation\nAbsolute Lymphocyte Count (ALC)\n500 cells/L\nMaintain dosage\n<500 cells/L\nInterrupt OLUMIANT until ALC 500 cells/L\nAbsolute Neutrophil Count (ANC)\n1000 cells/L\nMaintain dosage\n<1000 cells/L\nInterrupt OLUMIANT until ANC 1000 cells/L\nHemoglobin\n8 g/dL\nMaintain dosage\n<8 g/dL\nInterrupt OLUMIANT until hemoglobin 8 g/dL\nTable 1: Dosage Modifications for Cytopenias and Anemia in Patients with Rheumatoid Arthritis or Alopecia Areata\nTable 1: Dosage Modifications for Cytopenias and Anemia in Patients with Rheumatoid Arthritis or Alopecia Areata\nLaboratory Analyte\nLaboratory Analyte Value\nRecommendation\nLaboratory Analyte\nLaboratory Analyte Value\nRecommendation\nLaboratory Analyte\nLaboratory Analyte\nLaboratory Analyte Value\nLaboratory Analyte Value\nRecommendation\nRecommendation\nAbsolute Lymphocyte Count (ALC)\n500 cells/L\nMaintain dosage\n<500 cells/L\nInterrupt OLUMIANT until ALC 500 cells/L\nAbsolute Neutrophil Count (ANC)\n1000 cells/L\nMaintain dosage\n<1000 cells/L\nInterrupt OLUMIANT until ANC 1000 cells/L\nHemoglobin\n8 g/dL\nMaintain dosage\n<8 g/dL\nInterrupt OLUMIANT until hemoglobin 8 g/dL\nAbsolute Lymphocyte Count (ALC)\n500 cells/L\nMaintain dosage\nAbsolute Lymphocyte Count (ALC)\nAbsolute Lymphocyte Count (ALC)\n500 cells/L\n500 cells/L\nMaintain dosage\nMaintain dosage\n<500 cells/L\nInterrupt OLUMIANT until ALC 500 cells/L\n<500 cells/L\n<500 cells/L\nInterrupt OLUMIANT until ALC 500 cells/L\nInterrupt OLUMIANT until ALC 500 cells/L\nAbsolute Neutrophil Count (ANC)\n1000 cells/L\nMaintain dosage\nAbsolute Neutrophil Count (ANC)\nAbsolute Neutrophil Count (ANC)\n1000 cells/L\n1000 cells/L\nMaintain dosage\nMaintain dosage\n<1000 cells/L\nInterrupt OLUMIANT until ANC 1000 cells/L\n<1000 cells/L\n<1000 cells/L\nInterrupt OLUMIANT until ANC 1000 cells/L\nInterrupt OLUMIANT until ANC 1000 cells/L\nHemoglobin\n8 g/dL\nMaintain dosage\nHemoglobin\nHemoglobin\n8 g/dL\n8 g/dL\nMaintain dosage\nMaintain dosage\n<8 g/dL\nInterrupt OLUMIANT until hemoglobin 8 g/dL\n<8 g/dL\n<8 g/dL\nInterrupt OLUMIANT until hemoglobin 8 g/dL\nInterrupt OLUMIANT until hemoglobin 8 g/dL\nCOVID-19\nCOVID-19\nMonitor patients for signs and symptoms of new infections during treatment with OLUMIANT. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered [see Warnings and Precautions (5.1)].\nDosage modifications for patients with COVID-19 and cytopenias are described in Table 2.\nMonitor patients for signs and symptoms of new infections during treatment with OLUMIANT. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered [see Warnings and Precautions (5.1)].\nMonitor patients for signs and symptoms of new infections during treatment with OLUMIANT. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered [see Warnings and Precautions (5.1)].\nDosage modifications for patients with COVID-19 and cytopenias are described in Table 2.\nDosage modifications for patients with COVID-19 and cytopenias are described in Table 2.\nTable 2: Dosage Modifications for Cytopenias in Patients with COVID-19\nLaboratory Analyte\nLaboratory Analyte Value\nRecommendation\nAbsolute Lymphocyte Count (ALC)\n200 cells/L\nMaintain dosage\n<200 cells/L\nInterrupt OLUMIANT until ALC 200 cells/L\nAbsolute Neutrophil Count (ANC)\n500 cells/L\nMaintain dosage\n<500 cells/L\nInterrupt OLUMIANT until ANC 500 cells/L\nTable 2: Dosage Modifications for Cytopenias in Patients with COVID-19\nTable 2: Dosage Modifications for Cytopenias in Patients with COVID-19\nLaboratory Analyte\nLaboratory Analyte Value\nRecommendation\nLaboratory Analyte\nLaboratory Analyte Value\nRecommendation\nLaboratory Analyte\nLaboratory Analyte\nLaboratory Analyte Value\nLaboratory Analyte Value\nRecommendation\nRecommendation\nAbsolute Lymphocyte Count (ALC)\n200 cells/L\nMaintain dosage\n<200 cells/L\nInterrupt OLUMIANT until ALC 200 cells/L\nAbsolute Neutrophil Count (ANC)\n500 cells/L\nMaintain dosage\n<500 cells/L\nInterrupt OLUMIANT until ANC 500 cells/L\nAbsolute Lymphocyte Count (ALC)\n200 cells/L\nMaintain dosage\nAbsolute Lymphocyte Count (ALC)\nAbsolute Lymphocyte Count (ALC)\n200 cells/L\n200 cells/L\nMaintain dosage\nMaintain dosage\n<200 cells/L\nInterrupt OLUMIANT until ALC 200 cells/L\n<200 cells/L\n<200 cells/L\nInterrupt OLUMIANT until ALC 200 cells/L\nInterrupt OLUMIANT until ALC 200 cells/L\nAbsolute Neutrophil Count (ANC)\n500 cells/L\nMaintain dosage\nAbsolute Neutrophil Count (ANC)\nAbsolute Neutrophil Count (ANC)\n500 cells/L\n500 cells/L\nMaintain dosage\nMaintain dosage\n<500 cells/L\nInterrupt OLUMIANT until ANC 500 cells/L\n<500 cells/L\n<500 cells/L\nInterrupt OLUMIANT until ANC 500 cells/L\nInterrupt OLUMIANT until ANC 500 cells/L\n2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment\n2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment\nRheumatoid Arthritis\nRheumatoid Arthritis\nRenal Impairment\nRenal Impairment\nDosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3.\nDosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3.\nTable 3: Dosage Modifications for Patients with Rheumatoid Arthritis and Renal Impairment\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nMild\n60 <90 mL/minute/1.73 m2\n2 mg once daily\nModerate\n30 - <60 mL/min/1.73 m2\n1 mg once daily\nSevere\n<30 mL/minute/1.73 m2\nNot recommended\nTable 3: Dosage Modifications for Patients with Rheumatoid Arthritis and Renal Impairment\nTable 3: Dosage Modifications for Patients with Rheumatoid Arthritis and Renal Impairment\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRenal Impairment Stage\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRecommendation\nMild\n60 <90 mL/minute/1.73 m2\n2 mg once daily\nModerate\n30 - <60 mL/min/1.73 m2\n1 mg once daily\nSevere\n<30 mL/minute/1.73 m2\nNot recommended\nMild\n60 <90 mL/minute/1.73 m2\n2 mg once daily\nMild\nMild\n60 <90 mL/minute/1.73 m2\n60 <90 mL/minute/1.73 m\n2\n2\n2 mg once daily\n2 mg once daily\nModerate\n30 - <60 mL/min/1.73 m2\n1 mg once daily\nModerate\nModerate\n30 - <60 mL/min/1.73 m2\n30 - <60 mL/min/1.73 m\n2\n2\n1 mg once daily\n1 mg once daily\nSevere\n<30 mL/minute/1.73 m2\nNot recommended\nSevere\nSevere\n<30 mL/minute/1.73 m2\n<30 mL/minute/1.73 m\n2\n2\nNot recommended\nNot recommended\nHepatic Impairment\nHepatic Impairment\nOLUMIANT is not recommended for use in patients with severe hepatic impairment.\nInterrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nOLUMIANT is not recommended for use in patients with severe hepatic impairment.\nOLUMIANT is not recommended for use in patients with severe hepatic impairment.\nInterrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nInterrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nCOVID-19\nCOVID-19\nRenal Impairment\nRenal Impairment\nDosage modifications for patients with COVID-19 and renal impairment are described in Table 4.\nDosage modifications for patients with COVID-19 and renal impairment are described in Table 4.\nDosage modifications for patients with COVID-19 and renal impairment are described in Table 4.\nTable 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nMild\n60 - <90 mL/min/1.73 m2\n4 mg once daily\nModerate\n30 - <60 mL/min/1.73 m2\n2 mg once daily\nSevere\n15 - <30 mL/min/1.73 m2\n1 mg once daily\nEnd Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury\n<15 mL/min/1.73 m2\nNot recommended\nTable 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment\nTable 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRenal Impairment Stage\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRecommendation\nMild\n60 - <90 mL/min/1.73 m2\n4 mg once daily\nModerate\n30 - <60 mL/min/1.73 m2\n2 mg once daily\nSevere\n15 - <30 mL/min/1.73 m2\n1 mg once daily\nEnd Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury\n<15 mL/min/1.73 m2\nNot recommended\nMild\n60 - <90 mL/min/1.73 m2\n4 mg once daily\nMild\nMild\n60 - <90 mL/min/1.73 m2\n60 - <90 mL/min/1.73 m\n2\n2\n4 mg once daily\n4 mg once daily\nModerate\n30 - <60 mL/min/1.73 m2\n2 mg once daily\nModerate\nModerate\n30 - <60 mL/min/1.73 m2\n30 - <60 mL/min/1.73 m\n2\n2\n2 mg once daily\n2 mg once daily\nSevere\n15 - <30 mL/min/1.73 m2\n1 mg once daily\nSevere\nSevere\n15 - <30 mL/min/1.73 m2\n15 - <30 mL/min/1.73 m\n2\n2\n1 mg once daily\n1 mg once daily\nEnd Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury\n<15 mL/min/1.73 m2\nNot recommended\nEnd Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury\nEnd Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury\n<15 mL/min/1.73 m2\n<15 mL/min/1.73 m\n2\n2\nNot recommended\nNot recommended\nHepatic Impairment\nHepatic Impairment\nIt is not known if dosage adjustment is needed in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.\nInterrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nIt is not known if dosage adjustment is needed in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.\nIt is not known if dosage adjustment is needed in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.\nInterrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nInterrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nAlopecia Areata\nAlopecia Areata\nRenal Impairment\nRenal Impairment\nDosage modifications for patients with alopecia areata and renal impairment are described in Table 5.\nDosage modifications for patients with alopecia areata and renal impairment are described in Table 5.\nTable 5: Dosage Modifications for Patients with Alopecia Areata and Renal Impairment\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nIf the recommended dosage is 2 mg once daily\nIf the recommended dosage is 4 mg once daily\nMild\n60 <90 mL/minute/1.73 m2\nMaintain dosage\nModerate\n30 <60 mL/min/1.73 m2\nReduce to 1 mg once daily\nReduce to 2 mg once daily\nSevere\n<30 mL/minute/1.73 m2\nNot recommended\nTable 5: Dosage Modifications for Patients with Alopecia Areata and Renal Impairment\nTable 5: Dosage Modifications for Patients with Alopecia Areata and Renal Impairment\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nIf the recommended dosage is 2 mg once daily\nIf the recommended dosage is 4 mg once daily\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRenal Impairment Stage\nRenal Impairment Stage\nEstimated Glomerular Filtration Rate (eGFR)\nEstimated Glomerular Filtration Rate (eGFR)\nRecommendation\nRecommendation\nIf the recommended dosage is 2 mg once daily\nIf the recommended dosage is 4 mg once daily\nIf the recommended dosage is 2 mg once daily\nIf the recommended dosage is 2 mg once daily\nIf the recommended dosage is 4 mg once daily\nIf the recommended dosage is 4 mg once daily\nMild\n60 <90 mL/minute/1.73 m2\nMaintain dosage\nModerate\n30 <60 mL/min/1.73 m2\nReduce to 1 mg once daily\nReduce to 2 mg once daily\nSevere\n<30 mL/minute/1.73 m2\nNot recommended\nMild\n60 <90 mL/minute/1.73 m2\nMaintain dosage\nMild\nMild\n60 <90 mL/minute/1.73 m2\n60 <90 mL/minute/1.73 m\n2\n2\nMaintain dosage\nMaintain dosage\nModerate\n30 <60 mL/min/1.73 m2\nReduce to 1 mg once daily\nReduce to 2 mg once daily\nModerate\nModerate\n30 <60 mL/min/1.73 m2\n30 <60 mL/min/1.73 m\n2\n2\nReduce to 1 mg once daily\nReduce to 1 mg once daily\nReduce to 2 mg once daily\nReduce to 2 mg once daily\nSevere\n<30 mL/minute/1.73 m2\nNot recommended\nSevere\nSevere\n<30 mL/minute/1.73 m2\n<30 mL/minute/1.73 m\n2\n2\nNot recommended\nNot recommended\nHepatic Impairment\nHepatic Impairment\nOLUMIANT is not recommended for use in patients with severe hepatic impairment.\nInterrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nOLUMIANT is not recommended for use in patients with severe hepatic impairment.\nOLUMIANT is not recommended for use in patients with severe hepatic impairment.\nInterrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\nInterrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].\n2.7 Dosage Modifications Due to Drug Interactions\n2.7 Dosage Modifications Due to Drug Interactions\nRheumatoid Arthritis, COVID-19 or Alopecia Areata\nRheumatoid Arthritis, COVID-19 or Alopecia Areata\nThe recommended dosage of OLUMIANT in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, are shown in Table 6 [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].\nThe recommended dosage of OLUMIANT in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, are shown in Table 6 [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].\nTable 6: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients With Rheumatoid Arthritis, COVID-19 or Alopecia Areata\nConcomitant Medication\nRecommendation\nStrong OAT3 inhibitors (e.g., probenecid)\nIf the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.\nIf the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.\nIf the recommended dosage is 1 mg once daily, consider discontinuing probenecid.\nTable 6: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients With Rheumatoid Arthritis, COVID-19 or Alopecia Areata\nTable 6: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients With Rheumatoid Arthritis, COVID-19 or Alopecia Areata\nConcomitant Medication\nRecommendation\nConcomitant Medication\nRecommendation\nConcomitant Medication\nConcomitant Medication\nRecommendation\nRecommendation\nStrong OAT3 inhibitors (e.g., probenecid)\nIf the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.\nIf the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.\nIf the recommended dosage is 1 mg once daily, consider discontinuing probenecid.\nStrong OAT3 inhibitors (e.g., probenecid)\nIf the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.\nStrong OAT3 inhibitors (e.g., probenecid)\nStrong OAT3 inhibitors (e.g., probenecid)\nIf the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.\nIf the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.\nIf the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.\nIf the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.\nIf the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.\nIf the recommended dosage is 1 mg once daily, consider discontinuing probenecid.\nIf the recommended dosage is 1 mg once daily, consider discontinuing probenecid.\nIf the recommended dosage is 1 mg once daily, consider discontinuing probenecid.\n2.8 Alternative Administration for Patients Unable to Swallow Tablets\n2.8 Alternative Administration for Patients Unable to Swallow Tablets\nFor patients who are unable to swallow whole tablets, an alternative mode of administration may be considered:\nFor patients who are unable to swallow whole tablets, an alternative mode of administration may be considered:\nOral dispersion\nGastrostomy tube (G tube)\nNasogastric tube (NG tube) or orogastric tube (OG tube)\nOral dispersion\nOral dispersion\nGastrostomy tube (G tube)\nGastrostomy tube (G tube)\nNasogastric tube (NG tube) or orogastric tube (OG tube)\nNasogastric tube (NG tube) or orogastric tube (OG tube)\nIntact tablets are not hazardous. Tablets may be crushed to facilitate dispersion. It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours.\nIntact tablets are not hazardous. Tablets may be crushed to facilitate dispersion. It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours.\nPreparation Instructions for Alternative Administration:\nPreparation Instructions for Alternative Administration:\nOral administration of dispersed tablets in water: For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (Table 7).\nAdministration via G tube: For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).\nAdministration via NG or OG tube: For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).\nOral administration of dispersed tablets in water: For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (Table 7).\nOral administration of dispersed tablets in water: For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (Table 7).\nAdministration via G tube: For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).\nAdministration via G tube: For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).\nAdministration via NG or OG tube: For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).\nAdministration via NG or OG tube: For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).\nTable 7: Dispersion and Rinse Volume for Alternative Administration\nAdministration via\nDispersion Volume\nContainer Rinse Volume\nOral dispersion\n10 mL\n10 m\nTable 7: Dispersion and Rinse Volume for Alternative Administration\nTable 7: Dispersion and Rinse Volume for Alternative Administration\nAdministration via\nDispersion Volume\nContainer Rinse Volume\nAdministration via\nDispersion Volume\nContainer Rinse Volume\nAdministration via\nAdministration via\nDispersion Volume\nDispersion Volume\nContainer Rinse Volume\nContainer Rinse Volume\nOral dispersion\n10 mL\n10 m\nOral dispersion\n10 mL\n10 m\nOral dispersion\nOral dispersion\n10 mL\n10 mL\n10 m\n10 m",
      "dosageFormsAndStrengths": "3 DOSAGE FORMS AND STRENGTHS\n3 DOSAGE FORMS AND STRENGTHS\nOLUMIANT is available as debossed, film-coated tablets:\nOLUMIANT is available as debossed, film-coated tablets:\n1 mg tablet: Contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with \"Lilly\" on one side and \"1\" on the other.\n2 mg tablet: Contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with \"Lilly\" on one side and \"2\" on the other.\n4 mg tablet: Contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with \"Lilly\" on one side and \"4\" on the other.\n1 mg tablet: Contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with \"Lilly\" on one side and \"1\" on the other.\n1 mg tablet: Contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with \"Lilly\" on one side and \"1\" on the other.\n2 mg tablet: Contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with \"Lilly\" on one side and \"2\" on the other.\n2 mg tablet: Contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with \"Lilly\" on one side and \"2\" on the other.\n4 mg tablet: Contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with \"Lilly\" on one side and \"4\" on the other.\n4 mg tablet: Contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with \"Lilly\" on one side and \"4\" on the other.",
      "warningsAndPrecautions": "5.1 Serious Infections\n5.1 Serious Infections\nSerious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients with rheumatoid arthritis receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection [see Adverse Reactions (6.1)]. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.\nSerious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients with rheumatoid arthritis receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection [see Adverse Reactions (6.1)]. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.\nAvoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:\nAvoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:\nwith chronic or recurrent infection\nwho have been exposed to tuberculosis\nwith a history of a serious or an opportunistic infection\nwho have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or\nwith underlying conditions that may predispose them to infection.\nwith chronic or recurrent infection\nwith chronic or recurrent infection\nwho have been exposed to tuberculosis\nwho have been exposed to tuberculosis\nwith a history of a serious or an opportunistic infection\nwith a history of a serious or an opportunistic infection\nwho have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or\nwho have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or\nwith underlying conditions that may predispose them to infection.\nwith underlying conditions that may predispose them to infection.\nIn patients with rheumatoid arthritis or alopecia areata, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis or alopecia areata, if the patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. Do not resume OLUMIANT until the infection is controlled.\nIn patients with rheumatoid arthritis or alopecia areata, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis or alopecia areata, if the patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. Do not resume OLUMIANT until the infection is controlled.\nIn patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with OLUMIANT. There is limited information regarding the use of OLUMIANT in patients with COVID-19 and concomitant active serious infections. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered.\nIn patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with OLUMIANT. There is limited information regarding the use of OLUMIANT in patients with COVID-19 and concomitant active serious infections. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered.\nTuberculosis\nTuberculosis\nEvaluate patients for active infection prior to administration of OLUMIANT. OLUMIANT should not be given to patients with active TB.\nEvaluate patients for active infection prior to administration of OLUMIANT. OLUMIANT should not be given to patients with active TB.\nTest patients with rheumatoid arthritis or alopecia areata for latent tuberculosis. Patients with rheumatoid arthritis or alopecia areata and latent tuberculosis (TB) should be treated with standard antimycobacterial therapy before initiating OLUMIANT. Consider anti-TB therapy prior to initiation of OLUMIANT in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.\nTest patients with rheumatoid arthritis or alopecia areata for latent tuberculosis. Patients with rheumatoid arthritis or alopecia areata and latent tuberculosis (TB) should be treated with standard antimycobacterial therapy before initiating OLUMIANT. Consider anti-TB therapy prior to initiation of OLUMIANT in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.\nDuring OLUMIANT use, monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.\nDuring OLUMIANT use, monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.\nViral Reactivation\nViral Reactivation\nViral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with OLUMIANT. If a patient develops herpes zoster, interrupt OLUMIANT treatment until the episode resolves.\nViral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with OLUMIANT. If a patient develops herpes zoster, interrupt OLUMIANT treatment until the episode resolves.\nThe impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. In clinical trials in patients with rheumatoid arthritis or alopecia areata, patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA were permitted to enroll. Patients with positive hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with OLUMIANT.\nThe impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. In clinical trials in patients with rheumatoid arthritis or alopecia areata, patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA were permitted to enroll. Patients with positive hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with OLUMIANT.\n5.2 Mortality\n5.2 Mortality\nIn a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT.\nIn a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT.\n5.3 Malignancy and Lymphoproliferative Disorders\n5.3 Malignancy and Lymphoproliferative Disorders\nMalignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)].\nMalignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)].\nIn a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.\nIn a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.\nConsider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.\nConsider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.\nNon-melanoma skin cancers\nNon-melanoma skin cancers\nNon-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.\nNon-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.\n5.4 Major Adverse Cardiovascular Events\n5.4 Major Adverse Cardiovascular Events\nIn a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.\nIn a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.\nConsider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.\nConsider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.\n5.5 Thrombosis\n5.5 Thrombosis\nThrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with OLUMIANT. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.\nThrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with OLUMIANT. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.\nIf clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately. Avoid OLUMIANT in patients that may be at increased risk of thrombosis.\nIf clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately. Avoid OLUMIANT in patients that may be at increased risk of thrombosis.\n5.6 Hypersensitivity\n5.6 Hypersensitivity\nReactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction [see Adverse Reactions (6.2)].\nReactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction [see Adverse Reactions (6.2)].\n5.7 Gastrointestinal Perforations\n5.7 Gastrointestinal Perforations\nGastrointestinal perforations have been reported in clinical studies with OLUMIANT.\nGastrointestinal perforations have been reported in clinical studies with OLUMIANT.\nMonitor OLUMIANT-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Evaluate promptly patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.\nMonitor OLUMIANT-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Evaluate promptly patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.\n5.8 Laboratory Abnormalities\n5.8 Laboratory Abnormalities\nNeutropenia Treatment with OLUMIANT was associated with an increased incidence of neutropenia (ANC less than 1000cells/mm3) compared to placebo.\nNeutropenia Treatment with OLUMIANT was associated with an increased incidence of neutropenia (ANC less than 1000cells/mm\n3\n3\n) compared to placebo.\nIn patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ANC less than 1000cells/mm3.\nIn patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ANC less than 1000cells/mm\n3\n3\n.\nIn patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ANC less than 1000cells/mm3. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 500cells/mm3.\nIn patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ANC less than 1000cells/mm\n3\n3\n. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 500cells/mm\n3\n3\n.\nEvaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ANC [see Dosage and Administration (2.1, 2.5) and Adverse Reactions (6.1)].\nEvaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ANC [see Dosage and Administration (2.1, 2.5) and Adverse Reactions (6.1)].\nLymphopenia ALC less than 500cells/mm3 were reported in OLUMIANT clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with OLUMIANT, but not placebo.\nLymphopenia ALC less than 500cells/mm\n3\n3\nwere reported in OLUMIANT clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with OLUMIANT, but not placebo.\nIn patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ALC less than 500cells/mm3.\nIn patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ALC less than 500cells/mm\n3\n3\n.\nIn patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ALC less than 200cells/mm3. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ALC less than 200cells/mm3.\nIn patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ALC less than 200cells/mm\n3\n3\n. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ALC less than 200cells/mm\n3\n3\n.\nEvaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ALC [see Dosage and Administration (2.1, 2.5)].\nEvaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ALC [see Dosage and Administration (2.1, 2.5)].\nAnemia Decreases in hemoglobin levels to less than 8g/dL were reported in OLUMIANT clinical trials. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with hemoglobin less than 8g/dL. Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on hemoglobin levels [see Dosage and Administration (2.1, 2.5)].\nAnemia Decreases in hemoglobin levels to less than 8g/dL were reported in OLUMIANT clinical trials. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with hemoglobin less than 8g/dL. Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on hemoglobin levels [see Dosage and Administration (2.1, 2.5)].\nIn patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with hemoglobin less than 8g/dL.\nIn patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with hemoglobin less than 8g/dL.\nLiver Enzyme Elevations Treatment with OLUMIANT was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT 5 times the upper limit of normal (ULN) and increases of AST 10 times the ULN were observed in patients in OLUMIANT clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt OLUMIANT until this diagnosis is excluded [see Adverse Reactions (6.1)].\nLiver Enzyme Elevations Treatment with OLUMIANT was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT 5 times the upper limit of normal (ULN) and increases of AST 10 times the ULN were observed in patients in OLUMIANT clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt OLUMIANT until this diagnosis is excluded [see Adverse Reactions (6.1)].\nLipid Elevations Treatment with OLUMIANT was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Assessment of lipid parameters should be performed approximately 12weeks following OLUMIANT initiation in patients with rheumatoid arthritis or alopecia areata [see Adverse Reactions (6.1)]. Manage patients according to clinical guidelines for the management of hyperlipidemia.\nLipid Elevations Treatment with OLUMIANT was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Assessment of lipid parameters should be performed approximately 12weeks following OLUMIANT initiation in patients with rheumatoid arthritis or alopecia areata [see Adverse Reactions (6.1)]. Manage patients according to clinical guidelines for the management of hyperlipidemia.\n5.9 Vaccinations\n5.9 Vaccinations\nAvoid use of live vaccines with OLUMIANT. Update immunizations in patients with rheumatoid arthritis or alopecia areata prior to initiating OLUMIANT therapy in agreement with current immunization guidelines.\nAvoid use of live vaccines with OLUMIANT. Update immunizations in patients with rheumatoid arthritis or alopecia areata prior to initiating OLUMIANT therapy in agreement with current immunization guidelines.",
      "adverseReactions": "The following clinically significant adverse reactions are described elsewhere in the labeling:\nThe following clinically significant adverse reactions are described elsewhere in the labeling:\nSerious Infections [see Warnings and Precautions (5.1)]\nMortality [see Warnings and Precautions (5.2)]\nMalignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)]\nMajor Adverse Cardiovascular Events [see Warnings and Precautions (5.4)]\nThrombosis [see Warnings and Precautions (5.5)]\nHypersensitivity [see Warnings and Precautions (5.6)]\nGastrointestinal Perforations [see Warnings and Precautions (5.7)]\nLaboratory Abnormalities [see Warnings and Precautions (5.8)]\nSerious Infections [see Warnings and Precautions (5.1)]\nSerious Infections [see Warnings and Precautions (5.1)]\nMortality [see Warnings and Precautions (5.2)]\nMortality [see Warnings and Precautions (5.2)]\nMalignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)]\nMalignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)]\nMajor Adverse Cardiovascular Events [see Warnings and Precautions (5.4)]\nMajor Adverse Cardiovascular Events [see Warnings and Precautions (5.4)]\nThrombosis [see Warnings and Precautions (5.5)]\nThrombosis [see Warnings and Precautions (5.5)]\nHypersensitivity [see Warnings and Precautions (5.6)]\nHypersensitivity [see Warnings and Precautions (5.6)]\nGastrointestinal Perforations [see Warnings and Precautions (5.7)]\nGastrointestinal Perforations [see Warnings and Precautions (5.7)]\nLaboratory Abnormalities [see Warnings and Precautions (5.8)]\nLaboratory Abnormalities [see Warnings and Precautions (5.8)]\n6.1 Clinical Trials Experience\n6.1 Clinical Trials Experience\nBecause clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.\nBecause clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.\nAdverse Reactions in Patients with Rheumatoid Arthritis\nAdverse Reactions in Patients with Rheumatoid Arthritis\nThe safety of OLUMIANT was evaluated in six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study in patients with moderately to severely active RA. Patients were randomized to placebo (1070 patients), OLUMIANT 2mg (479 patients), or baricitinib 4mg (997 patients).\nThe safety of OLUMIANT was evaluated in six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study in patients with moderately to severely active RA. Patients were randomized to placebo (1070 patients), OLUMIANT 2mg (479 patients), or baricitinib 4mg (997 patients).\nPatients could be switched to baricitinib 4mg from placebo or OLUMIANT 2mg from as early as Week 12 depending on the study design. All patients initially randomized to placebo were switched to baricitinib 4mg by Week 24.\nPatients could be switched to baricitinib 4mg from placebo or OLUMIANT 2mg from as early as Week 12 depending on the study design. All patients initially randomized to placebo were switched to baricitinib 4mg by Week 24.\nDuring the 16-week treatment period, adverse events leading to discontinuation of treatment were reported by 35 patients (11.4 per 100 patient-years) treated with placebo, 17 patients (12.1 per 100 patient-years) with OLUMIANT 2mg, and 40 patients (13.4 per 100 patient-years) treated with baricitinib 4mg.\nDuring the 16-week treatment period, adverse events leading to discontinuation of treatment were reported by 35 patients (11.4 per 100 patient-years) treated with placebo, 17 patients (12.1 per 100 patient-years) with OLUMIANT 2mg, and 40 patients (13.4 per 100 patient-years) treated with baricitinib 4mg.\nDuring 0 to 52-week exposure, adverse events leading to discontinuation of treatment were reported by 31 patients (9.2 per 100 patient-years) with OLUMIANT 2mg, and 92 patients (10.2 per 100 patient-years) treated with baricitinib 4mg.\nDuring 0 to 52-week exposure, adverse events leading to discontinuation of treatment were reported by 31 patients (9.2 per 100 patient-years) with OLUMIANT 2mg, and 92 patients (10.2 per 100 patient-years) treated with baricitinib 4mg.\nOverall Infections During the 16-week treatment period, infections were reported by 253 patients (82.1 per 100 patient-years) treated with placebo, 139 patients (99.1 per 100 patient-years) treated with OLUMIANT 2mg, and 298 patients (100.1 per 100 patient-years) treated with baricitinib 4mg.\nOverall Infections During the 16-week treatment period, infections were reported by 253 patients (82.1 per 100 patient-years) treated with placebo, 139 patients (99.1 per 100 patient-years) treated with OLUMIANT 2mg, and 298 patients (100.1 per 100 patient-years) treated with baricitinib 4mg.\nDuring 0 to 52-week exposure, infections were reported by 200 patients (59.6 per 100 patient-years) treated with OLUMIANT 2mg, and 500 patients (55.3 per 100 patient-years) treated with baricitinib 4mg.\nDuring 0 to 52-week exposure, infections were reported by 200 patients (59.6 per 100 patient-years) treated with OLUMIANT 2mg, and 500 patients (55.3 per 100 patient-years) treated with baricitinib 4mg.\nIn the 0 to 52-week exposure population, the most commonly reported infections with OLUMIANT were viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, and bronchitis.\nIn the 0 to 52-week exposure population, the most commonly reported infections with OLUMIANT were viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, and bronchitis.\nSerious Infections During the 16-week treatment period, serious infections were reported in 13 patients (4.2 per 100 patient-years) treated with placebo, 5 patients (3.6 per 100 patient-years) treated with OLUMIANT 2mg, and 11 patients (3.7 per 100 patient-years) treated with baricitinib 4mg.\nSerious Infections During the 16-week treatment period, serious infections were reported in 13 patients (4.2 per 100 patient-years) treated with placebo, 5 patients (3.6 per 100 patient-years) treated with OLUMIANT 2mg, and 11 patients (3.7 per 100 patient-years) treated with baricitinib 4mg.\nDuring 0 to 52-week exposure, serious infections were reported in 14 patients (4.2 per 100 patient-years) treated with OLUMIANT 2mg and 32 patients (3.5 per 100 patient-years) treated with baricitinib 4mg.\nDuring 0 to 52-week exposure, serious infections were reported in 14 patients (4.2 per 100 patient-years) treated with OLUMIANT 2mg and 32 patients (3.5 per 100 patient-years) treated with baricitinib 4mg.\nIn the 0 to 52-week exposure population, the most commonly reported serious infections with OLUMIANT were pneumonia, herpes zoster, and urinary tract infection [see Warnings and Precautions (5.1)].\nIn the 0 to 52-week exposure population, the most commonly reported serious infections with OLUMIANT were pneumonia, herpes zoster, and urinary tract infection [see Warnings and Precautions (5.1)].\nTuberculosis During the 16-week treatment period, no events of tuberculosis were reported.\nTuberculosis During the 16-week treatment period, no events of tuberculosis were reported.\nDuring 0 to 52-week exposure, events of tuberculosis were reported in 0 patients treated with OLUMIANT 2mg and 1 patient (0.1 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.1)].\nDuring 0 to 52-week exposure, events of tuberculosis were reported in 0 patients treated with OLUMIANT 2mg and 1 patient (0.1 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.1)].\nCases of disseminated tuberculosis were also reported.\nCases of disseminated tuberculosis were also reported.\nOpportunistic Infections (excluding tuberculosis) During the 16-week treatment period, opportunistic infections were reported in 2 patients (0.6 per 100 patient-years) treated with placebo, 0 patients treated with OLUMIANT 2mg and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4mg. During 0 to 52-week exposure, opportunistic infections were reported in 1 patient (0.3 per 100 patient-years) treated with OLUMIANT 2mg and 5 patients (0.6 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.1)].\nOpportunistic Infections (excluding tuberculosis) During the 16-week treatment period, opportunistic infections were reported in 2 patients (0.6 per 100 patient-years) treated with placebo, 0 patients treated with OLUMIANT 2mg and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4mg. During 0 to 52-week exposure, opportunistic infections were reported in 1 patient (0.3 per 100 patient-years) treated with OLUMIANT 2mg and 5 patients (0.6 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.1)].\nMalignancies\nMalignancies\nDuring the 16-week treatment period, malignancies excluding non-melanoma skin cancers (NMSC) were reported in 0 patients treated with placebo, 1 patient (0.7 per 100 patient-years) treated with OLUMIANT 2mg, and 1 patient (0.3 per 100 patient-years) treated with baricitinib 4mg.\nDuring the 16-week treatment period, malignancies excluding non-melanoma skin cancers (NMSC) were reported in 0 patients treated with placebo, 1 patient (0.7 per 100 patient-years) treated with OLUMIANT 2mg, and 1 patient (0.3 per 100 patient-years) treated with baricitinib 4mg.\nDuring the 0 to 52-week treatment period, malignancies excluding NMSC were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2mg and 6 patients (0.7 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.3)].\nDuring the 0 to 52-week treatment period, malignancies excluding NMSC were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2mg and 6 patients (0.7 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.3)].\nThrombosis\nThrombosis\nVenous Thrombosis During the 16-week treatment period, venous thromboses (deep vein thrombosis or pulmonary embolism) were reported in 0 patients treated with placebo, 0 patients treated with OLUMIANT 2mg, and 5 patients (1.7 per 100 patient-years) treated with baricitinib 4mg. During the 0 to 52-week treatment period, venous thromboses were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 7 patients (0.8 per 100 patient-years) treated with baricitinib 4mg.\nVenous Thrombosis During the 16-week treatment period, venous thromboses (deep vein thrombosis or pulmonary embolism) were reported in 0 patients treated with placebo, 0 patients treated with OLUMIANT 2mg, and 5 patients (1.7 per 100 patient-years) treated with baricitinib 4mg. During the 0 to 52-week treatment period, venous thromboses were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 7 patients (0.8 per 100 patient-years) treated with baricitinib 4mg.\nArterial Thrombosis During the 16-week treatment period, arterial thromboses were reported in 1 patient treated with placebo (0.3 per 100 patient-years), 2 patients (1.4 per 100 patient-years) treated with OLUMIANT 2mg, and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4mg. During the 0 to 52-week treatment period, arterial thromboses were reported in 3 patients (0.9 per 100 patient-years) treated with OLUMIANT 2mg and 3 patients (0.3 per 100 patient-years) treated with baricitinib 4mg.\nArterial Thrombosis During the 16-week treatment period, arterial thromboses were reported in 1 patient treated with placebo (0.3 per 100 patient-years), 2 patients (1.4 per 100 patient-years) treated with OLUMIANT 2mg, and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4mg. During the 0 to 52-week treatment period, arterial thromboses were reported in 3 patients (0.9 per 100 patient-years) treated with OLUMIANT 2mg and 3 patients (0.3 per 100 patient-years) treated with baricitinib 4mg.\nLaboratory Abnormalities\nLaboratory Abnormalities\nNeutropenia During the 16-week treatment period, neutrophil counts below 1000 cells/mm3 occurred in 0% of patients treated with placebo, 0.6% of patients treated with OLUMIANT 2mg, and 0.3% of patients treated with baricitinib 4mg. There were no neutrophil counts below 500 cells/mm3 observed in any treatment group [see Warnings and Precautions (5.1, 5.8)].\nNeutropenia During the 16-week treatment period, neutrophil counts below 1000 cells/mm\n3\n3\noccurred in 0% of patients treated with placebo, 0.6% of patients treated with OLUMIANT 2mg, and 0.3% of patients treated with baricitinib 4mg. There were no neutrophil counts below 500 cells/mm\n3\n3\nobserved in any treatment group [see Warnings and Precautions (5.1, 5.8)].\nPlatelet Elevations During the 16-week treatment period, increases in platelet counts above 600,000 cells/mm3 occurred in 1.1% of patients treated with placebo, 1.1% of patients treated with OLUMIANT 2mg, and 2.0% of patients treated with baricitinib 4mg. Mean platelet count increased by 3000 cells/mm3 at 16 weeks in patients treated with placebo, by 15,000 cells/mm3 at 16 weeks in patients treated with OLUMIANT 2mg and by 23,000 cells/mm3 in patients treated with baricitinib 4mg.\nPlatelet Elevations During the 16-week treatment period, increases in platelet counts above 600,000 cells/mm\n3\n3\noccurred in 1.1% of patients treated with placebo, 1.1% of patients treated with OLUMIANT 2mg, and 2.0% of patients treated with baricitinib 4mg. Mean platelet count increased by 3000 cells/mm\n3\n3\nat 16 weeks in patients treated with placebo, by 15,000 cells/mm\n3\n3\nat 16 weeks in patients treated with OLUMIANT 2mg and by 23,000 cells/mm\n3\n3\nin patients treated with baricitinib 4mg.\nLiver Enzyme Elevations Events of increases in liver enzymes 3 times the ULN were observed in patients treated with OLUMIANT [see Warnings and Precautions (5.8)].\nLiver Enzyme Elevations Events of increases in liver enzymes 3 times the ULN were observed in patients treated with OLUMIANT [see Warnings and Precautions (5.8)].\nDuring the 16-week treatment period, ALT elevations 3 times the ULN occurred in 1.0% of patients treated with placebo, 1.7% of patients treated with OLUMIANT 2mg, and 1.4% of patients treated with baricitinib 4mg.\nDuring the 16-week treatment period, AST elevations 3 times the ULN occurred in 0.8% of patients treated with placebo, 1.3% of patients treated with OLUMIANT 2mg, and 0.8% of patients treated with baricitinib 4mg.\nIn a phase 3 study of DMARD naive patients, during the 24-week treatment period, ALT and AST elevations 3 times the ULN occurred in 1.9% and 0% of patients treated with methotrexate monotherapy, 1.9% and 1.3% of patients treated with baricitinib 4mg monotherapy, and 4.7% and 1.9% of patients treated with baricitinib 4mg plus methotrexate.\nDuring the 16-week treatment period, ALT elevations 3 times the ULN occurred in 1.0% of patients treated with placebo, 1.7% of patients treated with OLUMIANT 2mg, and 1.4% of patients treated with baricitinib 4mg.\nDuring the 16-week treatment period, ALT elevations 3 times the ULN occurred in 1.0% of patients treated with placebo, 1.7% of patients treated with OLUMIANT 2mg, and 1.4% of patients treated with baricitinib 4mg.\nDuring the 16-week treatment period, AST elevations 3 times the ULN occurred in 0.8% of patients treated with placebo, 1.3% of patients treated with OLUMIANT 2mg, and 0.8% of patients treated with baricitinib 4mg.\nDuring the 16-week treatment period, AST elevations 3 times the ULN occurred in 0.8% of patients treated with placebo, 1.3% of patients treated with OLUMIANT 2mg, and 0.8% of patients treated with baricitinib 4mg.\nIn a phase 3 study of DMARD naive patients, during the 24-week treatment period, ALT and AST elevations 3 times the ULN occurred in 1.9% and 0% of patients treated with methotrexate monotherapy, 1.9% and 1.3% of patients treated with baricitinib 4mg monotherapy, and 4.7% and 1.9% of patients treated with baricitinib 4mg plus methotrexate.\nIn a phase 3 study of DMARD naive patients, during the 24-week treatment period, ALT and AST elevations 3 times the ULN occurred in 1.9% and 0% of patients treated with methotrexate monotherapy, 1.9% and 1.3% of patients treated with baricitinib 4mg monotherapy, and 4.7% and 1.9% of patients treated with baricitinib 4mg plus methotrexate.\nLipid Elevations In controlled clinical trials, OLUMIANT treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During the 12-week treatment period, changes in lipid parameters are summarized below:\nLipid Elevations In controlled clinical trials, OLUMIANT treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During the 12-week treatment period, changes in lipid parameters are summarized below:\nMean LDL cholesterol increased by 8 mg/dL in patients treated with OLUMIANT 2mg and by 14 mg/dL in patients treated with baricitinib 4mg.\nMean HDL cholesterol increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 9 mg/dL in patients treated with baricitinib 4mg.\nThe mean LDL/HDL ratio remained stable.\nMean triglycerides increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 15 mg/dL in patients treated with baricitinib 4mg.\nMean LDL cholesterol increased by 8 mg/dL in patients treated with OLUMIANT 2mg and by 14 mg/dL in patients treated with baricitinib 4mg.\nMean LDL cholesterol increased by 8 mg/dL in patients treated with OLUMIANT 2mg and by 14 mg/dL in patients treated with baricitinib 4mg.\nMean HDL cholesterol increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 9 mg/dL in patients treated with baricitinib 4mg.\nMean HDL cholesterol increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 9 mg/dL in patients treated with baricitinib 4mg.\nThe mean LDL/HDL ratio remained stable.\nThe mean LDL/HDL ratio remained stable.\nMean triglycerides increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 15 mg/dL in patients treated with baricitinib 4mg.\nMean triglycerides increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 15 mg/dL in patients treated with baricitinib 4mg.\n[See Warnings and Precautions (5.8)].\n[See Warnings and Precautions (5.8)].\nCreatine Phosphokinase (CPK) OLUMIANT treatment was associated with increases in CPK within one week of starting OLUMIANT and plateauing after 8 to 12 weeks. At 16 weeks, the mean change in CPK for OLUMIANT 2mg and baricitinib 4mg was 37 IU/L and 52 IU/L, respectively.\nCreatine Phosphokinase (CPK) OLUMIANT treatment was associated with increases in CPK within one week of starting OLUMIANT and plateauing after 8 to 12 weeks. At 16 weeks, the mean change in CPK for OLUMIANT 2mg and baricitinib 4mg was 37 IU/L and 52 IU/L, respectively.\nCreatinine In controlled clinical trials, dose-related increases in serum creatinine were observed with OLUMIANT treatment. At 52 weeks, the mean increase in serum creatinine was less than 0.1 mg/dL with baricitinib 4mg. The clinical significance of the observed serum creatinine increases is unknown.\nCreatinine In controlled clinical trials, dose-related increases in serum creatinine were observed with OLUMIANT treatment. At 52 weeks, the mean increase in serum creatinine was less than 0.1 mg/dL with baricitinib 4mg. The clinical significance of the observed serum creatinine increases is unknown.\nOther Adverse Reactions\nOther Adverse Reactions\nOther adverse reactions are summarized in Table 8.\nOther adverse reactions are summarized in Table 8.\nTable 8: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2mg and Baricitinib 4mg Treated Patients in Placebo-Controlled Trials for Rheumatoid Arthritis\nEvents\nPlacebo\nOLUMIANT 2 mg\nBaricitinib 4 mg\nUpper respiratory tract infectionsa\n11.7%\n16.3%\n14.7%\nNausea\n1.6%\n2.7%\n2.8%\nHerpes simplexb\n0.7%\n0.8%\n1.8%\nHerpes zoster\n0.4%\n1.0%\n1.4%\na Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.\nb Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.\nTable 8: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2mg and Baricitinib 4mg Treated Patients in Placebo-Controlled Trials for Rheumatoid Arthritis\nTable 8: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2mg and Baricitinib 4mg Treated Patients in Placebo-Controlled Trials for Rheumatoid Arthritis\nEvents\nPlacebo\nOLUMIANT 2 mg\nBaricitinib 4 mg\nEvents\nPlacebo\nOLUMIANT 2 mg\nBaricitinib 4 mg\nEvents\nEvents\nPlacebo\nPlacebo\nOLUMIANT 2 mg\nOLUMIANT 2 mg\nBaricitinib 4 mg\nBaricitinib 4 mg\nUpper respiratory tract infectionsa\n11.7%\n16.3%\n14.7%\nNausea\n1.6%\n2.7%\n2.8%\nHerpes simplexb\n0.7%\n0.8%\n1.8%\nHerpes zoster\n0.4%\n1.0%\n1.4%\nUpper respiratory tract infectionsa\n11.7%\n16.3%\n14.7%\nUpper respiratory tract infectionsa\nUpper respiratory tract infections\na\na\n11.7%\n11.7%\n16.3%\n16.3%\n14.7%\n14.7%\nNausea\n1.6%\n2.7%\n2.8%\nNausea\nNausea\n1.6%\n1.6%\n2.7%\n2.7%\n2.8%\n2.8%\nHerpes simplexb\n0.7%\n0.8%\n1.8%\nHerpes simplexb\nHerpes simplex\nb\nb\n0.7%\n0.7%\n0.8%\n0.8%\n1.8%\n1.8%\nHerpes zoster\n0.4%\n1.0%\n1.4%\nHerpes zoster\nHerpes zoster\n0.4%\n0.4%\n1.0%\n1.0%\n1.4%\n1.4%\na Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.\nb Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.\na Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.\na Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.\na Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.\na Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.\nb Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.\nb Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.\nb Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.\nb Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.\nAdditional adverse drug reactions occurring in fewer than 1% of patients: acne.\nAdditional adverse drug reactions occurring in fewer than 1% of patients: acne.\nAdverse Reactions in Patients with COVID-19\nAdverse Reactions in Patients with COVID-19\nThe safety of OLUMIANT was evaluated in two randomized, double-blind, placebo-controlled clinical trials of hospitalized adults with COVID-19 for up to 29 days, in which 1307 patients received at least one dose of OLUMIANT 4 mg once daily, and 1310 patients received placebo, for up to 14 days or until hospital discharge, whichever occurred first. In these studies, prophylaxis for venous thromboembolic event (VTEs) was recommended or required for all patients unless a major contraindication was noted.\nThe safety of OLUMIANT was evaluated in two randomized, double-blind, placebo-controlled clinical trials of hospitalized adults with COVID-19 for up to 29 days, in which 1307 patients received at least one dose of OLUMIANT 4 mg once daily, and 1310 patients received placebo, for up to 14 days or until hospital discharge, whichever occurred first. In these studies, prophylaxis for venous thromboembolic event (VTEs) was recommended or required for all patients unless a major contraindication was noted.\nOverall, the safety profile observed in patients with COVID-19 treated with OLUMIANT was consistent with the safety profile in patients with rheumatoid arthritis.\nOverall, the safety profile observed in patients with COVID-19 treated with OLUMIANT was consistent with the safety profile in patients with rheumatoid arthritis.\nOverall Infections During the first 29 days of the randomized clinical trials, infections were reported in 194 patients (14.8%) treated with OLUMIANT 4mg and by 219 patients (16.7%) treated with placebo. The most commonly reported infection with OLUMIANT was pneumonia (3.1%).\nOverall Infections During the first 29 days of the randomized clinical trials, infections were reported in 194 patients (14.8%) treated with OLUMIANT 4mg and by 219 patients (16.7%) treated with placebo. The most commonly reported infection with OLUMIANT was pneumonia (3.1%).\nSerious Infections During the first 29 days of the randomized clinical trials, serious infections were reported in 98 patients (7.5%) treated with OLUMIANT 4mg and 120 patients (9.2%) treated with placebo. The most commonly reported serious infections with OLUMIANT were COVID-19 pneumonia (2.1%) and septic shock (2.1%).\nSerious Infections During the first 29 days of the randomized clinical trials, serious infections were reported in 98 patients (7.5%) treated with OLUMIANT 4mg and 120 patients (9.2%) treated with placebo. The most commonly reported serious infections with OLUMIANT were COVID-19 pneumonia (2.1%) and septic shock (2.1%).\nOpportunistic Infections During the first 29 days of the randomized clinical trials, opportunistic infections were reported in 12 patients (0.9%) treated with OLUMIANT 4mg and 14 patients (1.1%) treated with placebo. Tuberculosis was reported in 1 patient (0.1%) treated with OLUMIANT 4mg and 0 patients treated with placebo.\nOpportunistic Infections During the first 29 days of the randomized clinical trials, opportunistic infections were reported in 12 patients (0.9%) treated with OLUMIANT 4mg and 14 patients (1.1%) treated with placebo. Tuberculosis was reported in 1 patient (0.1%) treated with OLUMIANT 4mg and 0 patients treated with placebo.\nVenous Thrombosis Events - During the first 29 days of the randomized clinical trials, pulmonary embolism was reported in 20 patients (1.5%) treated with OLUMIANT 4mg and 11 patients (0.8%) treated with placebo. Deep vein thrombosis was reported in 20 patients (1.5%) treated with OLUMIANT 4mg and 18 patients (1.4%) treated with placebo.\nVenous Thrombosis Events - During the first 29 days of the randomized clinical trials, pulmonary embolism was reported in 20 patients (1.5%) treated with OLUMIANT 4mg and 11 patients (0.8%) treated with placebo. Deep vein thrombosis was reported in 20 patients (1.5%) treated with OLUMIANT 4mg and 18 patients (1.4%) treated with placebo.\nAdverse drug reactions in greater than or equal to 1% of patients in trials for COVID-19 are summarized in Table 9.\nAdverse drug reactions in greater than or equal to 1% of patients in trials for COVID-19 are summarized in Table 9.\nTable 9: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Patients Treated with OLUMIANT 4mg During the First 29 Days in Placebo-Controlled Trials for COVID-19\nPlacebo N = 1310 n (%)\nOLUMIANT 4 mg N = 1307 n (%)\nALT 3 x ULNa\n201 (16.0%)\n230 (18.1%)\nAST 3 x ULNa\n117 (9.4%)\n149 (11.8%)\nThrombocytosis >600,000 cells/mm3a\n34 (4.6%)\n59 (7.9%)</\nTable 9: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Patients Treated with OLUMIANT 4mg During the First 29 Days in Placebo-Controlled Trials for COVID-19\nTable 9: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Patients Treated with OLUMIANT 4mg During the First 29 Days in Placebo-Controlled Trials for COVID-19\nPlacebo N = 1310 n (%)\nOLUMIANT 4 mg N = 1307 n (%)\nPlacebo N = 1310 n (%)\nOLUMIANT 4 mg N = 1307 n (%)\nPlacebo N = 1310 n (%)\nPlacebo N = 1310 n (%)\nOLUMIANT 4 mg N = 1307 n (%)\nOLUMIANT 4 mg N = 1307 n (%)\nALT 3 x ULNa\n201 (16.0%)\n230 (18.1%)\nAST 3 x ULNa\n117 (9.4%)\n149 (11.8%)\nThrombocytosis >600,000 cells/mm3a\n34 (4.6%)\n59 (7.9%)</\nALT 3 x ULNa\n201 (16.0%)\n230 (18.1%)\nALT 3 x ULNa\nALT 3 x ULN\na\na\n201 (16.0%)\n201 (16.0%)\n230 (18.1%)\n230 (18.1%)\nAST 3 x ULNa\n117 (9.4%)\n149 (11.8%)\nAST 3 x ULNa\nAST 3 x ULN\na\na\n117 (9.4%)\n117 (9.4%)\n149 (11.8%)\n149 (11.8%)\nThrombocytosis >600,000 cells/mm3a\n34 (4.6%)\n59 (7.9%)</\nThrombocytosis >600,000 cells/mm3a\nThrombocytosis >600,000 cells/mm\n3\n3\na\na\n34 (4.6%)\n34 (4.6%)\n59 (7.9%)</\n59 (7.9%)</",
      "drugInteractions": "7 DRUG INTERACTIONS\n7 DRUG INTERACTIONS\n7.1 Strong OAT3 Inhibitors\n7.1 Strong OAT3 Inhibitors\nBaricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose [see Dosage and Administration (2.2, 2.3) and Clinical Pharmacology (12.3)].\nBaricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose [see Dosage and Administration (2.2, 2.3) and Clinical Pharmacology (12.3)].\n7.2 Other JAK Inhibitors or Biologic DMARDs\n7.2 Other JAK Inhibitors or Biologic DMARDs\nOLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs [see Indications and Usage (1.1, 1.2)].\nOLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs [see Indications and Usage (1.1, 1.2)].",
      "clinicalPharmacology": "12 CLINICAL PHARMACOLOGY\n12 CLINICAL PHARMACOLOGY\n12.1 Mechanism of Action\n12.1 Mechanism of Action\nBaricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.\nBaricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.\nJAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.\nJAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.\n12.2 Pharmacodynamics\n12.2 Pharmacodynamics\nBaricitinib inhibition of IL-6 induced STAT3 phosphorylation Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1hour after dosing, which returned to near baseline by 24hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.\nBaricitinib inhibition of IL-6 induced STAT3 phosphorylation Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1hour after dosing, which returned to near baseline by 24hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.\nImmunoglobulins Mean serum IgG, IgM, and IgA values decreased by 12weeks after starting treatment with OLUMIANT, and remained stable through at least 52weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.\nImmunoglobulins Mean serum IgG, IgM, and IgA values decreased by 12weeks after starting treatment with OLUMIANT, and remained stable through at least 52weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.\nC-reactive protein In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.\nC-reactive protein In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.\nCardiac Electrophysiology At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.\nCardiac Electrophysiology At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.\n12.3 Pharmacokinetics\n12.3 Pharmacokinetics\nFollowing oral administration of OLUMIANT, peak plasma concentrations are reached approximately at 1hour. A dose-proportional increase in systemic exposure was observed in the therapeutic dose range. The pharmacokinetics of baricitinib do not change over time. Steady-state concentrations are achieved in 2 to 3days with minimal accumulation after once-daily administration.\nFollowing oral administration of OLUMIANT, peak plasma concentrations are reached approximately at 1hour. A dose-proportional increase in systemic exposure was observed in the therapeutic dose range. The pharmacokinetics of baricitinib do not change over time. Steady-state concentrations are achieved in 2 to 3days with minimal accumulation after once-daily administration.\nAbsorption The absolute bioavailability of baricitinib is approximately 80%. An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean AUC and Cmax of baricitinib by approximately 11% and 18%, respectively, and delayed the tmax by 0.5hours. Administration with meals is not associated with a clinically relevant effect on exposure. In clinical studies, OLUMIANT was administered without regard to meals.\nAbsorption The absolute bioavailability of baricitinib is approximately 80%. An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean AUC and Cmax of baricitinib by approximately 11% and 18%, respectively, and delayed the tmax by 0.5hours. Administration with meals is not associated with a clinically relevant effect on exposure. In clinical studies, OLUMIANT was administered without regard to meals.\nDistribution After intravenous administration, the volume of distribution is 76L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.\nDistribution After intravenous administration, the volume of distribution is 76L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.\nElimination\nElimination\nRheumatoid Arthritis and Alopecia Areata: The total body clearance of baricitinib is 8.9L/h in patients with rheumatoid arthritis and 11L/h in patients with alopecia areata. Elimination half-life in patients with rheumatoid arthritis and alopecia areata is approximately 12to 16 hours.\nRheumatoid Arthritis and Alopecia Areata: The total body clearance of baricitinib is 8.9L/h in patients with rheumatoid arthritis and 11L/h in patients with alopecia areata. Elimination half-life in patients with rheumatoid arthritis and alopecia areata is approximately 12to 16 hours.\nCOVID-19: The total body clearance and half-life of baricitinib is 14.2L/h and 10.8 hours, respectively, in patients with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.\nCOVID-19: The total body clearance and half-life of baricitinib is 14.2L/h and 10.8 hours, respectively, in patients with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.\nMetabolism Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in plasma.\nMetabolism Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in plasma.\nExcretion Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib was excreted predominately as unchanged drug in urine (69%) and feces (15%).\nExcretion Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib was excreted predominately as unchanged drug in urine (69%) and feces (15%).\nSpecific Populations\nSpecific Populations\nEffects of Body Weight, Gender, Race, and Age\nEffects of Body Weight, Gender, Race, and Age\nBody weight, gender, race, ethnicity, and age did not have a clinically relevant effect on the PK (AUC and Cmax) of baricitinib (Figure 1). The mean effects of intrinsic factors on PK parameters (AUC and Cmax) were generally within the inter-subject PK variability of baricitinib. The inter-subject variabilities (% coefficients of variation) in AUC and Cmax of baricitinib are approximately 41% and 22%, respectively, in patients with rheumatoid arthritis [see Use in Specific Populations (8.5)].\nBody weight, gender, race, ethnicity, and age did not have a clinically relevant effect on the PK (AUC and Cmax) of baricitinib (Figure 1). The mean effects of intrinsic factors on PK parameters (AUC and Cmax) were generally within the inter-subject PK variability of baricitinib. The inter-subject variabilities (% coefficients of variation) in AUC and Cmax of baricitinib are approximately 41% and 22%, respectively, in patients with rheumatoid arthritis [see Use in Specific Populations (8.5)].\nPatients with Renal Impairment\nPatients with Renal Impairment\nBaricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild, moderate, severe, and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in Cmax were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) [see Use in Specific Populations (8.7)].\nBaricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild, moderate, severe, and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in Cmax were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) [see Use in Specific Populations (8.7)].\nPatients with Hepatic Impairment\nPatients with Hepatic Impairment\nBaricitinib systemic exposure and Cmax increased by 1.19- and 1.08-fold for the moderate hepatic impairment group, respectively, compared to subjects with normal hepatic function (Figure 1) [see Use in Specific Populations (8.6)].\nBaricitinib systemic exposure and Cmax increased by 1.19- and 1.08-fold for the moderate hepatic impairment group, respectively, compared to subjects with normal hepatic function (Figure 1) [see Use in Specific Populations (8.6)].\nFigure 1: Impact of Intrinsic Factors on Baricitinib Pharmacokineticsa, b\nFigure 1: Impact of Intrinsic Factors on Baricitinib Pharmacokineticsa, b\na Reference values for weight, age, gender, and race comparisons are 70kg, 54years, male, and white, respectively; reference groups for renal and hepatic impairment are subjects with normal renal and hepatic function, respectively.\na Reference values for weight, age, gender, and race comparisons are 70kg, 54years, male, and white, respectively; reference groups for renal and hepatic impairment are subjects with normal renal and hepatic function, respectively.\nb Effects of renal and hepatic impairment on baricitinib exposure were summarized from dedicated renal and hepatic impairment studies, respectively. Effects of other intrinsic factors on baricitinib exposure were summarized from population PK analysis.\nb Effects of renal and hepatic impairment on baricitinib exposure were summarized from dedicated renal and hepatic impairment studies, respectively. Effects of other intrinsic factors on baricitinib exposure were summarized from population PK analysis.\nc The recommended dose for patients with COVID-19 and severe renal impairment (eGFR 15 - <30mL/min/1.73m2) is 1 mg once daily. OLUMIANT is not recommended for use in patients with COVID-19 who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR <15mL/min/1.73m2). [see Dosage and Administration (2.6)]\nc The recommended dose for patients with COVID-19 and severe renal impairment (eGFR 15 - <30mL/min/1.73m2) is 1 mg once daily. OLUMIANT is not recommended for use in patients with COVID-19 who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR <15mL/min/1.73m2). [see Dosage and Administration (2.6)]\nDrug Interactions\nDrug Interactions\nPotential for Baricitinib to Influence the PK of Other Drugs\nPotential for Baricitinib to Influence the PK of Other Drugs\nIn vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6). In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib.\nIn vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6). In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib.\nIn vitro studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1. In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects on the PK of digoxin (Pgp substrate) or methotrexate (substrate of several transporters) when co-administered with baricitinib.\nIn vitro studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1. In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects on the PK of digoxin (Pgp substrate) or methotrexate (substrate of several transporters) when co-administered with baricitinib.\nExposure changes of drugs following co-administration with baricitinib are shown in Figure 2.\nExposure changes of drugs following co-administration with baricitinib are shown in Figure 2.\nFigure 2: Impact of Baricitinib on the Pharmacokinetics of Other Drugsa\nFigure 2: Impact of Baricitinib on the Pharmacokinetics of Other Drugsa\na Reference group is administration of concomitant drug alone.\na Reference group is administration of concomitant drug alone.\nPotential for Other Drugs to Influence the PK of Baricitinib\nPotential for Other Drugs to Influence the PK of Baricitinib\nIn vitro studies suggest that baricitinib is a CYP3A4 substrate. In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (CYP3A inducer).\nIn vitro studies suggest that baricitinib is a CYP3A4 substrate. In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (CYP3A inducer).\nIn vitro studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC0- with no effect on Cmax and tmax[see Dosage and Administration (2.2, 2.3) and Drug Interactions (7.1)]. However, simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib. In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib.\nIn vitro studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC0- with no effect on Cmax and tmax[see Dosage and Administration (2.2, 2.3) and Drug Interactions (7.1)]. However, simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib. In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib.\nExposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in Figure 3.\nExposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in Figure 3.\nFigure 3: Impact of Other Drugs on the Pharmacokinetics of Baricitinibb\nFigure 3: Impact of Other Drugs on the Pharmacokinetics of Baricitinibb\na Values are based on simulated studies.\na Values are based on simulated studies.\nb Reference group is administration of baricitinib alone.\nb Reference group is administration of baricitinib alone.",
      "clinicalStudies": "14 CLINICAL STUDIES\n14 CLINICAL STUDIES\n14.1 Rheumatoid Arthritis\n14.1 Rheumatoid Arthritis\nThe OLUMIANT clinical development program included two dose-ranging trials and four confirmatory phase3trials in patients with rheumatoid arthritis (RA). Although other doses have been studied, the recommended dosage of OLUMIANT is 2mg once daily.\nThe OLUMIANT clinical development program included two dose-ranging trials and four confirmatory phase3trials in patients with rheumatoid arthritis (RA). Although other doses have been studied, the recommended dosage of OLUMIANT is 2mg once daily.\nDose-Ranging Studies\nDose-Ranging Studies\nThe dose-ranging studies RA-1 (NCT01185353) and RA-2 (NCT01469013) included a 12-week randomized comparison of baricitinib 1, 2, 4, and 8mg orally once daily versus placebo in 301 and 145 patients, respectively.\nThe dose-ranging studies RA-1 (NCT01185353) and RA-2 (NCT01469013) included a 12-week randomized comparison of baricitinib 1, 2, 4, and 8mg orally once daily versus placebo in 301 and 145 patients, respectively.\nThe results from the dose-ranging studies are shown in Table 11. In dose-ranging Study RA-1, the observed ACR response was similar for baricitinib 1 and 2mg daily and for baricitinib 4 and 8mg daily, with the highest response for baricitinib 8mg daily. In dose-ranging Study RA-2, there was not a clear trend of dose response, with similar response rates for 1mg and 4mg and 2mg and 8mg.\nThe results from the dose-ranging studies are shown in Table 11. In dose-ranging Study RA-1, the observed ACR response was similar for baricitinib 1 and 2mg daily and for baricitinib 4 and 8mg daily, with the highest response for baricitinib 8mg daily. In dose-ranging Study RA-2, there was not a clear trend of dose response, with similar response rates for 1mg and 4mg and 2mg and 8mg.\nTable 11: Proportion of Patients with ACR20 Response at Week 12 in Dose-Ranging RA Studies% ACR20 RespondersDose-Ranging StudyPlaceboBaricitinib1 mg dailyBaricitinib2 mg dailyBaricitinib4 mg dailyBaricitinib8 mg dailyRA-1 (N=301)4157547578RA-2 (N=145)3167836788\nTable 11: Proportion of Patients with ACR20 Response at Week 12 in Dose-Ranging RA Studies\nTable 11: Proportion of Patients with ACR20 Response at Week 12 in Dose-Ranging RA Studies\n% ACR20 RespondersDose-Ranging StudyPlaceboBaricitinib1 mg dailyBaricitinib2 mg dailyBaricitinib4 mg dailyBaricitinib8 mg dailyRA-1 (N=301)4157547578RA-2 (N=145)3167836788\n% ACR20 Responders\n% ACR20 Responders\n% ACR20 Responders\nDose-Ranging StudyPlaceboBaricitinib1 mg dailyBaricitinib2 mg dailyBaricitinib4 mg dailyBaricitinib8 mg daily\nDose-Ranging Study\nDose-Ranging Study\nPlacebo\nPlacebo\nBaricitinib1 mg daily\nBaricitinib1 mg daily\nBaricitinib2 mg daily\nBaricitinib2 mg daily\nBaricitinib4 mg daily\nBaricitinib4 mg daily\nBaricitinib8 mg daily\nBaricitinib8 mg daily\nRA-1 (N=301)4157547578\nRA-1 (N=301)\nRA-1 (N=301)\n41\n41\n57\n57\n54\n54\n75\n75\n78\n78\nRA-2 (N=145)3167836788\nRA-2 (N=145)\nRA-2 (N=145)\n31\n31\n67\n67\n83\n83\n67\n67\n88\n88\nConfirmatory Studies\nConfirmatory Studies\nThe efficacy and safety of OLUMIANT 2mg once daily was assessed in two confirmatory phase 3 trials. These trials were randomized, double-blind, multicenter studies in patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR)/European League Against Rheumatism 2010 criteria. Patients over 18years of age were eligible if at least 6 tender and 6 swollen joints were present at baseline. The two studies (Studies RA-3 and RA-4) evaluated OLUMIANT 2mg and baricitinib 4mg.\nThe efficacy and safety of OLUMIANT 2mg once daily was assessed in two confirmatory phase 3 trials. These trials were randomized, double-blind, multicenter studies in patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR)/European League Against Rheumatism 2010 criteria. Patients over 18years of age were eligible if at least 6 tender and 6 swollen joints were present at baseline. The two studies (Studies RA-3 and RA-4) evaluated OLUMIANT 2mg and baricitinib 4mg.\nStudy RA-3 (NCT01721057) was a 24-week trial in 684patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to conventional DMARDs (cDMARDs). Patients received OLUMIANT 2mg or 4mg once daily or placebo added to existing background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week12.\nStudy RA-3 (NCT01721057) was a 24-week trial in 684patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to conventional DMARDs (cDMARDs). Patients received OLUMIANT 2mg or 4mg once daily or placebo added to existing background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week12.\nStudy RA-4 (NCT01721044) was a 24-week trial in 527patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to 1or moreTNF inhibitor therapies with or without other biologic DMARDs (TNFi-IR). Patients received OLUMIANT 2mg or baricitinib 4mg once daily or placebo added to background cDMARD treatment. From Week16, non-responding patients could be rescued to receive baricitinib 4mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week12.\nStudy RA-4 (NCT01721044) was a 24-week trial in 527patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to 1or moreTNF inhibitor therapies with or without other biologic DMARDs (TNFi-IR). Patients received OLUMIANT 2mg or baricitinib 4mg once daily or placebo added to background cDMARD treatment. From Week16, non-responding patients could be rescued to receive baricitinib 4mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week12.\nClinical Response\nClinical Response\nThe percentages of OLUMIANT-treated patients achieving ACR20, ACR50, and ACR70 responses, and Disease Activity Score (DAS28-CRP) <2.6 in Studies RA-3 and RA-4 are shown in Table 8.\nThe percentages of OLUMIANT-treated patients achieving ACR20, ACR50, and ACR70 responses, and Disease Activity Score (DAS28-CRP) <2.6 in Studies RA-3 and RA-4 are shown in Table 8.\nPatients treated with OLUMIANT had higher rates of ACR response and DAS28-CRP <2.6 versus placebo-treated patients at Week12 (Studies RA-3 and RA-4) (Table 12).\nPatients treated with OLUMIANT had higher rates of ACR response and DAS28-CRP <2.6 versus placebo-treated patients at Week12 (Studies RA-3 and RA-4) (Table 12).\nIn Study RA-4, higher ACR20 response rates (Figure 4) were observed as early as 1 week with OLUMIANT 2mg versus placebo.\nIn Study RA-4, higher ACR20 response rates (Figure 4) were observed as early as 1 week with OLUMIANT 2mg versus placebo.\nIn Study RA-4, the proportions of patients achieving DAS28-CRP <2.6 who had at least 3 active joints at the end of Week 24 were 18.2% and 10.5%, in the placebo and OLUMIANT 2mg arms, respectively.\nIn Study RA-4, the proportions of patients achieving DAS28-CRP <2.6 who had at least 3 active joints at the end of Week 24 were 18.2% and 10.5%, in the placebo and OLUMIANT 2mg arms, respectively.\nTable 12: Clinical Response in RA Studies RA-3 and RA-4aa Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.b 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).Percent of PatientscDMARD-IRTNFi-IRStudy RA-3Study RA-4Placebo + cDMARDsOLUMIANT2 mg/day + cDMARDs (95% CI)bPlacebo + cDMARDsOLUMIANT2 mg/day + cDMARDs (95% CI)bN228229176174ACR 20Week 12%396627 (18, 35)274922 (12, 32)Week 24%426119 (10, 28)274518 (8, 27)ACR 50Week 12%133421 (13, 28)82012 (5, 19)Week 24%214120 (12, 28)132310 (2, 18)ACR 70Week 12%31815 (9, 20)21311 (5, 16)Week 24%82517 (11, 24)31310 (4, 16)DAS28-CRP<2.6Week 12%926(10, 24)411(2, 12)Week 24%1131(13, 27)611(-1, 11)\nTable 12: Clinical Response in RA Studies RA-3 and RA-4a\nTable 12: Clinical Response in RA Studies RA-3 and RA-4a\na Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.b 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).\na Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.\na Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.\na Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.\na Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.\nb 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).\nb 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).\nb 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).\nb 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).\nPercent of PatientscDMARD-IRTNFi-IRStudy RA-3Study RA-4Placebo + cDMARDsOLUMIANT2 mg/day + cDMARDs (95% CI)bPlacebo + cDMARDsOLUMIANT2 mg/day + cDMARDs (95% CI)bN228229176174ACR 20Week 12%396627 (18, 35)274922 (12, 32)Week 24%426119 (10, 28)274518 (8, 27)ACR 50Week 12%133421 (13, 28)82012 (5, 19)Week 24%214120 (12, 28)132310 (2, 18)ACR 70Week 12%31815 (9, 20)21311 (5, 16)Week 24%82517 (11, 24)31310 (4, 16)DAS28-CRP<2.6Week 12%926(10, 24)411(2, 12)Week 24%1131(13, 27)611(-1, 11)\nPercent of Patients\nPercent of Patients\nPercent of Patients\ncDMARD-IRTNFi-IR\ncDMARD-IR\ncDMARD-IR\nTNFi-IR\nTNFi-IR\nStudy RA-3Study RA-4\nStudy RA-3\nStudy RA-3\nStudy RA-4\nStudy RA-4\nPlacebo + cDMARDsOLUMIANT2 mg/day + cDMARDs (95% CI)bPlacebo + cDMARDsOLUMIANT2 mg/day + cDMARDs (95% CI)b\nPlacebo + cDMARDs\nPlacebo + cDMARDs\nOLUMIANT2 mg/day + cDMARDs (95% CI)b\nOLUMIANT2 mg/day + cDMARDs (95% CI)b\nPlacebo + cDMARDs\nPlacebo + cDMARDs\nOLUMIANT2 mg/day + cDMARDs (95% CI)b\nOLUMIANT2 mg/day + cDMARDs (95% CI)b\nN228229176174\nN\nN\n228\n228\n229\n229\n176\n176\n174\n174\nACR 20\nACR 20\nACR 20\nWeek 12%396627 (18, 35)274922 (12, 32)\nWeek 12%\nWeek 12%\n39\n39\n6627 (18, 35)\n6627 (18, 35)\n27\n27\n4922 (12, 32)\n4922 (12, 32)\nWeek 24%426119 (10, 28)274518 (8, 27)\nWeek 24%\nWeek 24%\n42\n42\n6119 (10, 28)\n6119 (10, 28)\n27\n27\n4518 (8, 27)\n4518 (8, 27)\nACR 50\nACR 50\nACR 50\nWeek 12%133421 (13, 28)82012 (5, 19)\nWeek 12%\nWeek 12%\n13\n13\n3421 (13, 28)\n3421 (13, 28)\n8\n8\n2012 (5, 19)\n2012 (5, 19)\nWeek 24%214120 (12, 28)132310 (2, 18)\nWeek 24%\nWeek 24%\n21\n21\n4120 (12, 28)\n4120 (12, 28)\n13\n13\n2310 (2, 18)\n2310 (2, 18)\nACR 70\nACR 70\nACR 70\nWeek 12%31815 (9, 20)21311 (5, 16)\nWeek 12%\nWeek 12%\n3\n3\n1815 (9, 20)\n1815 (9, 20)\n2\n2\n1311 (5, 16)\n1311 (5, 16)\nWeek 24%82517 (11, 24)31310 (4, 16)\nWeek 24%\nWeek 24%\n8\n8\n2517 (11, 24)\n2517 (11, 24)\n3\n3\n1310 (4, 16)\n1310 (4, 16)\nDAS28-CRP<2.6\nDAS28-CRP<2.6\nDAS28-CRP<2.6\nWeek 12%926(10, 24)411(2, 12)\nWeek 12%\nWeek 12%\n9\n9\n26(10, 24)\n26(10, 24)\n4\n4\n11(2, 12)\n11(2, 12)\nWeek 24%1131(13, 27)611(-1, 11)\nWeek 24%\nWeek 24%\n11\n11\n31(13, 27)\n31(13, 27)\n6\n6\n11(-1, 11)\n11(-1, 11)\nThe effects of OLUMIANT treatment on the components of the ACR response criteria for Studies RA-3 and RA-4 are shown in Table 13.\nThe effects of OLUMIANT treatment on the components of the ACR response criteria for Studies RA-3 and RA-4 are shown in Table 13.\nTable 13: Components of ACR Response at Week 12 in RA Studies RA-3 and RA-4aa Data shown are mean (standard deviation).b Visual analog scale: 0=best, 100=worst.c Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.cDMARD-IRTNFi-IRStudy RA-3Study RA-4Placebo+ cDMARDsOLUMIANT2 mg/day+ cDMARDsPlacebo+ cDMARDsOLUMIANT2 mg/day+ cDMARDsN228229176174Number of Tender Joints (0-68) Baseline24 (15)24 (14)28 (16)31 (16) Week 1215 (14)11 (13)20 (16)19 (18)Number of Swollen Joints (0-66) Baseline13 (7)14 (9)17 (11)19 (12) Week 128 (8)5 (6)12 (10)10 (12)Painb Baseline57 (23)60 (21)65 (19)62 (22) Week 1243 (24)34 (25)55 (25)46 (28)Patient Global Assessmentb Baseline60 (21)62 (20)66 (19)67 (19) Week 1244 (23)36 (25)56 (25)46 (26)Physician Global Assessmentb Baseline62 (17)64 (17)67 (19)67 (17) Week 1241 (24)33 (22)50 (26)36 (24)Disability Index (HAQ-DI)c Baseline1.50 (0.60)1.51 (0.62)1.78 (0.57)1.71 (0.55) Week 121.17 (0.62)0.96 (0.69)1.59 (0.68)1.31 (0.72)hsCRP (mg/L) Baseline17.7 (20.4)18.2 (21.5)20.6 (25.3)19.9 (22.5) Week 1217.2 (19.3)8.6 (14.6)19.9 (23.0)13.5 (20.1)\nTable 13: Components of ACR Response at Week 12 in RA Studies RA-3 and RA-4a\nTable 13: Components of ACR Response at Week 12 in RA Studies RA-3 and RA-4a\na Data shown are mean (standard deviation).b Visual analog scale: 0=best, 100=worst.c Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.\na Data shown are mean (standard deviation).\na Data shown are mean (standard deviation).\na Data shown are mean (standard deviation).\na Data shown are mean (standard deviation).\nb Visual analog scale: 0=best, 100=worst.\nb Visual analog scale: 0=best, 100=worst.\nb Visual analog scale: 0=best, 100=worst.\nb Visual analog scale: 0=best, 100=worst.\nc Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.\nc Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.\nc Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.\nc Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.\ncDMARD-IRTNFi-IRStudy RA-3Study RA-4Placebo+ cDMARDsOLUMIANT2 mg/day+ cDMARDsPlacebo+ cDMARDsOLUMIANT2 mg/day+ cDMARDsN228229176174Number of Tender Joints (0-68) Baseline24 (15)24 (14)28 (16)31 (16) Week 1215 (14)11 (13)20 (16)19 (18)Number of Swollen Joints (0-66) Baseline13 (7)14 (9)17 (11)19 (12) Week 128 (8)5 (6)12 (10)10 (12)Painb Baseline57 (23)60 (21)65 (19)62 (22) Week 1243 (24)34 (25)55 (25)46 (28)Patient Global Assessmentb Baseline60 (21)62 (20)66 (19)67 (19) Week 1244 (23)36 (25)56 (25)46 (26)Physician Global Assessmentb Baseline62 (17)64 (17)67 (19)67 (17) Week 1241 (24)33 (22)50 (26)36 (24)Disability Index (HAQ-DI)c Baseline1.50 (0.60)1.51 (0.62)1.78 (0.57)1.71 (0.55) Week 121.17 (0.62)0.96 (0.69)1.59 (0.68)1.31 (0.72)hsCRP (mg/L) Baseline17.7 (20.4)18.2 (21.5)20.6 (25.3)19.9 (22.5) Week 1217.2 (19.3)8.6 (14.6)19.9 (23.0)13.5 (20.1)\ncDMARD-IRTNFi-IR\ncDMARD-IR\ncDMARD-IR\nTNFi-IR\nTNFi-IR\nStudy RA-3Study RA-4\nStudy RA-3\nStudy RA-3\nStudy RA-4\nStudy RA-4\nPlacebo+ cDMARDsOLUMIANT2 mg/day+ cDMARDsPlacebo+ cDMARDsOLUMIANT2 mg/day+ cDMARDs\nPlacebo+ cDMARDs\nPlacebo+ cDMARDs\nOLUMIANT2 mg/day+ cDMARDs\nOLUMIANT2 mg/day+ cDMARDs\nPlacebo+ cDMARDs\nPlacebo+ cDMARDs\nOLUMIANT2 mg/day+ cDMARDs\nOLUMIANT2 mg/day+ cDMARDs\nN228229176174\nN\nN\n228\n228\n229\n229\n176\n176\n174\n174\nNumber of Tender Joints (0-68)\nNumber of Tender Joints (0-68)\nNumber of Tender Joints (0-68)\nBaseline24 (15)24 (14)28 (16)31 (16)\nBaseline\nBaseline\n24 (15)\n24 (15)\n24 (14)\n24 (14)\n28 (16)\n28 (16)\n31 (16)\n31 (16)\nWeek 1215 (14)11 (13)20 (16)19 (18)\nWeek 12\nWeek 12\n15 (14)\n15 (14)\n11 (13)\n11 (13)\n20 (16)\n20 (16)\n19 (18)\n19 (18)\nNumber of Swollen Joints (0-66)\nNumber of Swollen Joints (0-66)\nNumber of Swollen Joints (0-66)\nBaseline13 (7)14 (9)17 (11)19 (12)\nBaseline\nBaseline\n13 (7)\n13 (7)\n14 (9)\n14 (9)\n17 (11)\n17 (11)\n19 (12)\n19 (12)\nWeek 128 (8)5 (6)12 (10)10 (12)\nWeek 12\nWeek 12\n8 (8)\n8 (8)\n5 (6)\n5 (6)\n12 (10)\n12 (10)\n10 (12)\n10 (12)\nPainb\nPainb\nPainb\nBaseline57 (23)60 (21)65 (19)62 (22)\nBaseline\nBaseline\n57 (23)\n57 (23)\n60 (21)\n60 (21)\n65 (19)\n65 (19)\n62 (22)\n62 (22)\nWeek 1243 (24)34 (25)55 (25)46 (28)\nWeek 12\nWeek 12\n43 (24)\n43 (24)\n34 (25)\n34 (25)\n55 (25)\n55 (25)\n46 (28)\n46 (28)\nPatient Global Assessmentb\nPatient Global Assessmentb\nPatient Global Assessmentb\nBaseline60 (21)62 (20)66 (19)67 (19)\nBaseline\nBaseline\n60 (21)\n60 (21)\n62 (20)\n62 (20)\n66 (19)\n66 (19)\n67 (19)\n67 (19)\nWeek 1244 (23)36 (25)56 (25)46 (26)\nWeek 12\nWeek 12\n44 (23)\n44 (23)\n36 (25)\n36 (25)\n56 (25)\n56 (25)\n46 (26)\n46 (26)\nPhysician Global Assessmentb\nPhysician Global Assessmentb\nPhysician Global Assessmentb\nBaseline62 (17)64 (17)67 (19)67 (17)\nBaseline\nBaseline\n62 (17)\n62 (17)\n64 (17)\n64 (17)\n67 (19)\n67 (19)\n67 (17)\n67 (17)\nWeek 1241 (24)33 (22)50 (26)36 (24)\nWeek 12\nWeek 12\n41 (24)\n41 (24)\n33 (22)\n33 (22)\n50 (26)\n50 (26)\n36 (24)\n36 (24)\nDisability Index (HAQ-DI)c\nDisability Index (HAQ-DI)c\nDisability Index (HAQ-DI)c\nBaseline1.50 (0.60)1.51 (0.62)1.78 (0.57)1.71 (0.55)\nBaseline\nBaseline\n1.50 (0.60)\n1.50 (0.60)\n1.51 (0.62)\n1.51 (0.62)\n1.78 (0.57)\n1.78 (0.57)\n1.71 (0.55)\n1.71 (0.55)\nWeek 121.17 (0.62)0.96 (0.69)1.59 (0.68)1.31 (0.72)\nWeek 12\nWeek 12\n1.17 (0.62)\n1.17 (0.62)\n0.96 (0.69)\n0.96 (0.69)\n1.59 (0.68)\n1.59 (0.68)\n1.31 (0.72)\n1.31 (0.72)\nhsCRP (mg/L)\nhsCRP (mg/L)\nhsCRP (mg/L)\nBaseline17.7 (20.4)18.2 (21.5)20.6 (25.3)19.9 (22.5)\nBaseline\nBaseline\n17.7 (20.4)\n17.7 (20.4)\n18.2 (21.5)\n18.2 (21.5)\n20.6 (25.3)\n20.6 (25.3)\n19.9 (22.5)\n19.9 (22.5)\nWeek 1217.2 (19.3)8.6 (14.6)19.9 (23.0)13.5 (20.1)\nWeek 12\nWeek 12\n17.2 (19.3)\n17.2 (19.3)\n8.6 (14.6)\n8.6 (14.6)\n19.9 (23.0)\n19.9 (23.0)\n13.5 (20.1)\n13.5 (20.1)\nFigure 4: Percent of RA Patients Achieving ACR20 in Study RA-4\nFigure 4: Percent of RA Patients Achieving ACR20 in Study RA-4\nPhysical Function Response\nPhysical Function Response\nImprovement in physical function was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Patients receiving OLUMIANT 2mg demonstrated greater improvement from baseline in physical functioning compared to placebo at Week 24. The mean difference (95% CI) from placebo in HAQ-DI change from baseline at Week24 was -0.24 (-0.35, -0.14) in Study RA-3 and -0.23 (-0.35, -0.12) in Study RA-4.\nImprovement in physical function was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Patients receiving OLUMIANT 2mg demonstrated greater improvement from baseline in physical functioning compared to placebo at Week 24. The mean difference (95% CI) from placebo in HAQ-DI change from baseline at Week24 was -0.24 (-0.35, -0.14) in Study RA-3 and -0.23 (-0.35, -0.12) in Study RA-4.\nOther Health Related Outcomes\nOther Health Related Outcomes\nGeneral health status was assessed by the Short Form health survey (SF-36). In Studies RA-3 and RA-4, compared to placebo, patients treated with OLUMIANT 2mg demonstrated greater improvement from baseline in the physical component summary (PCS) score and the physical function, role physical, bodily pain, vitality, and general health domains at Week 12, with no consistent improvements in the mental component summary (MCS) scores or the role emotional, mental health, and social functioning domains.\nGeneral health status was assessed by the Short Form health survey (SF-36). In Studies RA-3 and RA-4, compared to placebo, patients treated with OLUMIANT 2mg demonstrated greater improvement from baseline in the physical component summary (PCS) score and the physical function, role physical, bodily pain, vitality, and general health domains at Week 12, with no consistent improvements in the mental component summary (MCS) scores or the role emotional, mental health, and social functioning domains.\n14.2 COVID-19\n14.2 COVID-19\nThe efficacy and safety of baricitinib were assessed in 2Phase 3, randomized, double-blind, placebo-controlled clinical trials:\nThe efficacy and safety of baricitinib were assessed in 2Phase 3, randomized, double-blind, placebo-controlled clinical trials:\nCOVID I (NCT04401579), which evaluated the combination of baricitinib 4mg+remdesivir compared to placebo+remdesivir.COVID II (NCT04421027), which evaluated baricitinib 4mg compared to placebo. Patients could remain on background therapy, as defined per local guidelines. An additional exploratory sub-study in patients requiring invasive mechanical ventilation or ECMO at baseline was also conducted under this protocol and analyzed separately.\nCOVID I (NCT04401579), which evaluated the combination of baricitinib 4mg+remdesivir compared to placebo+remdesivir.\nCOVID I (NCT04401579), which evaluated the combination of baricitinib 4mg+remdesivir compared to placebo+remdesivir.\nCOVID II (NCT04421027), which evaluated baricitinib 4mg compared to placebo. Patients could remain on background therapy, as defined per local guidelines. An additional exploratory sub-study in patients requiring invasive mechanical ventilation or ECMO at baseline was also conducted under this protocol and analyzed separately.\nCOVID II (NCT04421027), which evaluated baricitinib 4mg compared to placebo. Patients could remain on background therapy, as defined per local guidelines. An additional exploratory sub-study in patients requiring invasive mechanical ventilation or ECMO at baseline was also conducted under this protocol and analyzed separately.\nCOVID I\nCOVID I\nA randomized, double-blind, placebo-controlled clinical trial (NCT04401579) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib plus remdesivir (n = 515) with placebo plus remdesivir (n=518). Patients had to have laboratory-confirmed SARS-CoV-2 infection as well as at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 94% on room air, a requirement for supplemental oxygen, or a requirement for mechanical ventilation or ECMO. Patients treated with the combination received the following regimen:\nA randomized, double-blind, placebo-controlled clinical trial (NCT04401579) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib plus remdesivir (n = 515) with placebo plus remdesivir (n=518). Patients had to have laboratory-confirmed SARS-CoV-2 infection as well as at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 94% on room air, a requirement for supplemental oxygen, or a requirement for mechanical ventilation or ECMO. Patients treated with the combination received the following regimen:\nBaricitinib 4 mg once daily (orally) for up to 14 days or until hospital discharge, whichever came firstRemdesivir 200 mg on Day 1 and 100 mg once daily (via intravenous infusion) on subsequent days for a total treatment duration of 10 days or until hospital discharge\nBaricitinib 4 mg once daily (orally) for up to 14 days or until hospital discharge, whichever came first\nBaricitinib 4 mg once daily (orally) for up to 14 days or until hospital discharge, whichever came first\nRemdesivir 200 mg on Day 1 and 100 mg once daily (via intravenous infusion) on subsequent days for a total treatment duration of 10 days or until hospital discharge\nRemdesivir 200 mg on Day 1 and 100 mg once daily (via intravenous infusion) on subsequent days for a total treatment duration of 10 days or until hospital discharge\nIn this study prophylaxis for venous thromboembolic event (VTEs) was recommended for all patients unless a major contraindication was noted.\nIn this study prophylaxis for venous thromboembolic event (VTEs) was recommended for all patients unless a major contraindication was noted.\nFor the overall population (N = 1033 patients) at randomization, mean age was 55 years (with 30% of patients aged 65 or older); 63% of patients were male, 51% were Hispanic or Latino, 48% were White, 15% were Black or African American, and 10% were Asian; 14% did not require supplemental oxygen, 55% required supplemental oxygen, 21% required non-invasive ventilation or high-flow oxygen, and 11% required invasive mechanical ventilation or ECMO. The most common comorbidities were obesity (56%), hypertension (52%), and type 2 diabetes (37%). Demographics and disease characteristics were balanced across the combination group and the placebo group.\nFor the overall population (N = 1033 patients) at randomization, mean age was 55 years (with 30% of patients aged 65 or older); 63% of patients were male, 51% were Hispanic or Latino, 48% were White, 15% were Black or African American, and 10% were Asian; 14% did not require supplemental oxygen, 55% required supplemental oxygen, 21% required non-invasive ventilation or high-flow oxygen, and 11% required invasive mechanical ventilation or ECMO. The most common comorbidities were obesity (56%), hypertension (52%), and type 2 diabetes (37%). Demographics and disease characteristics were balanced across the combination group and the placebo group.\nThe primary endpoint, for the intent to treat population, was time to recovery within 29 days after randomization. Recovery was defined as being discharged from the hospital without limitations on activities, being discharged from the hospital with limitations on activities and/or requiring home oxygen or hospitalized but not requiring supplemental oxygen and no longer requiring medical care. The key secondary endpoint was clinical status on Day 15 assessed on an 8-point ordinal scale (OS) consisting of the following categories:\nThe primary endpoint, for the intent to treat population, was time to recovery within 29 days after randomization. Recovery was defined as being discharged from the hospital without limitations on activities, being discharged from the hospital with limitations on activities and/or requiring home oxygen or hospitalized but not requiring supplemental oxygen and no longer requiring medical care. The key secondary endpoint was clinical status on Day 15 assessed on an 8-point ordinal scale (OS) consisting of the following categories:\nNot hospitalized, no limitations on activities [OS-1];Not hospitalized, limitation on activities and/or requiring home oxygen [OS-2];Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care [OS-3];Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) [OS 4];Hospitalized, requiring supplemental oxygen [OS 5];Hospitalized, on non-invasive ventilation or high-flow oxygen devices [OS 6];Hospitalized, on invasive mechanical ventilation or ECMO [OS 7]; andDeath [OS 8]\nNot hospitalized, no limitations on activities [OS-1];\nNot hospitalized, no limitations on activities [OS-1];\nNot hospitalized, limitation on activities and/or requiring home oxygen [OS-2];\nNot hospitalized, limitation on activities and/or requiring home oxygen [OS-2];\nHospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care [OS-3];\nHospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care [OS-3];\nHospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) [OS 4];\nHospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) [OS 4];\nHospitalized, requiring supplemental oxygen [OS 5];\nHospitalized, requiring supplemental oxygen [OS 5];\nHospitalized, on non-invasive ventilation or high-flow oxygen devices [OS 6];\nHospitalized, on non-invasive ventilation or high-flow oxygen devices [OS 6];\nHospitalized, on invasive mechanical ventilation or ECMO [OS 7]; and\nHospitalized, on invasive mechanical ventilation or ECMO [OS 7]; and\nDeath [OS 8]\nDeath [OS 8]\nFor the overall population, the median time to recovery (defined as discharged from hospital or hospitalized but not requiring supplemental oxygen or ongoing medical care) was 7 days for baricitinib + remdesivir compared to 8 days for placebo + remdesivir [hazard ratio: 1.16 (95% CI 1.01, 1.33); p = 0.035].\nFor the overall population, the median time to recovery (defined as discharged from hospital or hospitalized but not requiring supplemental oxygen or ongoing medical care) was 7 days for baricitinib + remdesivir compared to 8 days for placebo + remdesivir [hazard ratio: 1.16 (95% CI 1.01, 1.33); p = 0.035].\nPatients assigned to baricitinib + remdesivir were more likely to have a better clinical status (according to an 8-point ordinal scale) at Day 15 compared to patients assigned to placebo + remdesivir [odds ratio: 1.26 (95% CI 1.01, 1.57); p=0.044].\nPatients assigned to baricitinib + remdesivir were more likely to have a better clinical status (according to an 8-point ordinal scale) at Day 15 compared to patients assigned to placebo + remdesivir [odds ratio: 1.26 (95% CI 1.01, 1.57); p=0.044].\nThe proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation by Day 29 was lower in baricitinib + remdesivir (23%) compared to placebo + remdesivir (28%) [odds ratio: 0.74 (95% CI 0.56, 0.99); p = 0.039]. Patients who required non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO) at baseline needed to worsen by at least 1 point on an 8-point ordinal scale to progress.\nThe proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation by Day 29 was lower in baricitinib + remdesivir (23%) compared to placebo + remdesivir (28%) [odds ratio: 0.74 (95% CI 0.56, 0.99); p = 0.039]. Patients who required non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO) at baseline needed to worsen by at least 1 point on an 8-point ordinal scale to progress.\nThe proportion of patients who died by Day 29 was 4.7% (24/515) for baricitinib + remdesivir compared to 7.1% (37/518) for placebo + remdesivir [Kaplan Meier estimated difference in Day 29 probability of mortality: -2.6% (95% CI: -5.8%, 0.5%); hazard ratio = 0.65 (95% CI: 0.39, 1.09)].\nThe proportion of patients who died by Day 29 was 4.7% (24/515) for baricitinib + remdesivir compared to 7.1% (37/518) for placebo + remdesivir [Kaplan Meier estimated difference in Day 29 probability of mortality: -2.6% (95% CI: -5.8%, 0.5%); hazard ratio = 0.65 (95% CI: 0.39, 1.09)].\nCOVID II\nCOVID II\nA randomized, double-blind, placebo-controlled clinical trial (NCT04421027) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib 4mg once daily (n = 764) with placebo (n = 761) for 14 days or hospital discharge, whichever came first. Patients could remain on background standard of care, as defined per local guidelines, including antimalarials, antivirals, corticosteroids, and/or azithromycin. In this study prophylaxis for venous thromboembolic event (VTE) was required for all patients unless contraindicated.\nA randomized, double-blind, placebo-controlled clinical trial (NCT04421027) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib 4mg once daily (n = 764) with placebo (n = 761) for 14 days or hospital discharge, whichever came first. Patients could remain on background standard of care, as defined per local guidelines, including antimalarials, antivirals, corticosteroids, and/or azithromycin. In this study prophylaxis for venous thromboembolic event (VTE) was required for all patients unless contraindicated.\nThe most frequently used therapies at baseline were:\nThe most frequently used therapies at baseline were:\ncorticosteroids (79% of patients, mostly dexamethasone)remdesivir (19% of patients)\ncorticosteroids (79% of patients, mostly dexamethasone)\ncorticosteroids (79% of patients, mostly dexamethasone)\nremdesivir (19% of patients)\nremdesivir (19% of patients)\nPatients had to have laboratory-confirmed SARS-CoV-2 infection, at least one instance of elevation in at least one inflammatory marker above the upper limit of normal according to local laboratory ranges (CRP, D-dimer, LDH, ferritin), and at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 <94% on room air, evidence of active COVID infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate >24 breaths/min) or requirement for supplemental oxygen.\nPatients had to have laboratory-confirmed SARS-CoV-2 infection, at least one instance of elevation in at least one inflammatory marker above the upper limit of normal according to local laboratory ranges (CRP, D-dimer, LDH, ferritin), and at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 <94% on room air, evidence of active COVID infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate >24 breaths/min) or requirement for supplemental oxygen.\nFor the overall population (N = 1525 patients) at randomization, mean age was 58 years (with 33% of patients aged 65 or older); 63% of patients were male, 60% were White, 5% were Black or African American, 11% were Asian; 12% did not require supplemental oxygen (OS 4), 63% required supplemental oxygen (OS 5), 24% required non-invasive ventilation or high-flow oxygen (OS 6). The most common comorbidities were hypertension (48%), obesity (33%), and type 2 diabetes (29%). Demographics and disease characteristics were balanced across the baricitinib and placebo groups.\nFor the overall population (N = 1525 patients) at randomization, mean age was 58 years (with 33% of patients aged 65 or older); 63% of patients were male, 60% were White, 5% were Black or African American, 11% were Asian; 12% did not require supplemental oxygen (OS 4), 63% required supplemental oxygen (OS 5), 24% required non-invasive ventilation or high-flow oxygen (OS 6). The most common comorbidities were hypertension (48%), obesity (33%), and type 2 diabetes (29%). Demographics and disease characteristics were balanced across the baricitinib and placebo groups.\nThe primary endpoint was the proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation within the first 28-days of the study. Patients who required non-invasive ventilation/high-flow oxygen at baseline needed to worsen by at least 1 point on an 8-point OS to progress (refer to the description of COVID I for the definition of the 8-point OS). A key secondary endpoint was all-cause mortality by Day 28.\nThe primary endpoint was the proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation within the first 28-days of the study. Patients who required non-invasive ventilation/high-flow oxygen at baseline needed to worsen by at least 1 point on an 8-point OS to progress (refer to the description of COVID I for the definition of the 8-point OS). A key secondary endpoint was all-cause mortality by Day 28.\nThe estimated proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation was lower in patients treated with baricitinib (27.8%) compared to placebo (30.5%), but this effect was not statistically significant [odds ratio: 0.85 (95% CI 0.67, 1.08); p = 0.180].\nThe estimated proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation was lower in patients treated with baricitinib (27.8%) compared to placebo (30.5%), but this effect was not statistically significant [odds ratio: 0.85 (95% CI 0.67, 1.08); p = 0.180].\nThe proportion of patients who died by Day 28 was 8.1% (62/764) for baricitinib compared to 13.3% (101/761) for placebo [estimated difference in Day 28 probability of mortality = -4.9% (95% CI: -8.0%, -1.9%); hazard ratio = 0.56 (95% CI: 0.41, 0.77)].\nThe proportion of patients who died by Day 28 was 8.1% (62/764) for baricitinib compared to 13.3% (101/761) for placebo [estimated difference in Day 28 probability of mortality = -4.9% (95% CI: -8.0%, -1.9%); hazard ratio = 0.56 (95% CI: 0.41, 0.77)].\nCOVID II Exploratory Sub-Study\nCOVID II Exploratory Sub-Study\nIn a separate group of patients requiring invasive mechanical ventilation or ECMO at baseline and enrolled in an addendum to COVID II, a pre-specified exploratory analysis showed that the proportion who died by Day 28 was 39.2% (20/51) for baricitinib compared to 58.0% (29/50) for placebo [estimated difference in Day 28 risk of mortality = -18.8% (95% CI: -36.3%, 0.6%); hazard ratio = 0.54 (95% CI: 0.31, 0.96)].\nIn a separate group of patients requiring invasive mechanical ventilation or ECMO at baseline and enrolled in an addendum to COVID II, a pre-specified exploratory analysis showed that the proportion who died by Day 28 was 39.2% (20/51) for baricitinib compared to 58.0% (29/50) for placebo [estimated difference in Day 28 risk of mortality = -18.8% (95% CI: -36.3%, 0.6%); hazard ratio = 0.54 (95% CI: 0.31, 0.96)].\n14.3 Alopecia Areata\n14.3 Alopecia Areata\nTwo randomized, double-blind, placebo-controlled trials [Trials AA-1 (NCT03570749) and AA-2 (NCT03899259)] enrolled a total of 1200 patients, with alopecia areata (AA), who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months. The trials enrolled males 18 to 60 years of age and females 18 to 70 years of age. Among the patients enrolled, 61% were female, 2% were 65 years of age or older, and 52% were White, 36% were Asian, and 8% were Black. At baseline, 53% of patients had at least 95% scalp hair loss, 34% had their current episode lasting at least 4 years, 69% had significant gaps in eyebrow hair or no notable eyebrow hair, and 58% had significant gaps in eyelashes or no notable eyelashes.\nTwo randomized, double-blind, placebo-controlled trials [Trials AA-1 (NCT03570749) and AA-2 (NCT03899259)] enrolled a total of 1200 patients, with alopecia areata (AA), who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months. The trials enrolled males 18 to 60 years of age and females 18 to 70 years of age. Among the patients enrolled, 61% were female, 2% were 65 years of age or older, and 52% were White, 36% were Asian, and 8% were Black. At baseline, 53% of patients had at least 95% scalp hair loss, 34% had their current episode lasting at least 4 years, 69% had significant gaps in eyebrow hair or no notable eyebrow hair, and 58% had significant gaps in eyelashes or no notable eyelashes.\nIn the Phase 3 portion of Trial AA-1 and in Trial AA-2, patients received OLUMIANT 2 mg, OLUMIANT 4mg, or placebo once daily.\nIn the Phase 3 portion of Trial AA-1 and in Trial AA-2, patients received OLUMIANT 2 mg, OLUMIANT 4mg, or placebo once daily.\nBoth trials assessed the proportion of patients who achieved at least 80% scalp hair coverage (SALT score of 20) at Week 36 as the primary endpoint. Other outcomes at Week 36 included the proportion of patients who achieved at least 90% scalp hair coverage (SALT score of 10), patients with Scalp Hair Assessment PRO score of 0 or 1 with at least 2-point reduction on the 5-point scale, and assessments of eyebrow and eyelash hair loss.\nBoth trials assessed the proportion of patients who achieved at least 80% scalp hair coverage (SALT score of 20) at Week 36 as the primary endpoint. Other outcomes at Week 36 included the proportion of patients who achieved at least 90% scalp hair coverage (SALT score of 10), patients with Scalp Hair Assessment PRO score of 0 or 1 with at least 2-point reduction on the 5-point scale, and assessments of eyebrow and eyelash hair loss.\nClinical Response\nClinical Response\nThe results of the OLUMIANT trials (AA-1 and AA-2) are provided in Table 14 and Figure 5.\nThe results of the OLUMIANT trials (AA-1 and AA-2) are provided in Table 14 and Figure 5.\nTable 14: Clinical Response at Week 36 in Patients with Severe AAa Not statistically significant under the multiplicity control planb Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).Trial AA-1Trial AA-2PlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/dayPlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/dayNumber of subjects with at least 50% scalp hair loss at baselineN189184281156156234SALT 20 Difference from Placebo (95% CI)5%22%16%(10, 23)35%30%(23, 36)3%17%15%(8, 22)32%30%(23, 36)SALT 10 Difference from Placebo (95% CI)4%13%9%(3, 15)26%22%(16, 28)1%11%10%(5, 16)a24%23%(17, 29)Number of subjects reporting Scalp Hair Assessment PRO score 3 at baselineN181175275151149215Scalp Hair Assessment PRO score of 0 or 1b Difference from Placebo (95% CI)5%16%11%(5, 18)33%28%(21, 34)4%16%12%(5, 19)34%30%(23, 37)\nTable 14: Clinical Response at Week 36 in Patients with Severe AA\nTable 14: Clinical Response at Week 36 in Patients with Severe AA\na Not statistically significant under the multiplicity control planb Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).\na Not statistically significant under the multiplicity control plan\na Not statistically significant under the multiplicity control plan\na Not statistically significant under the multiplicity control plan\na Not statistically significant under the multiplicity control plan\nb Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).\nb Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).\nb Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).\nb Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).\nTrial AA-1Trial AA-2PlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/dayPlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/dayNumber of subjects with at least 50% scalp hair loss at baselineN189184281156156234SALT 20 Difference from Placebo (95% CI)5%22%16%(10, 23)35%30%(23, 36)3%17%15%(8, 22)32%30%(23, 36)SALT 10 Difference from Placebo (95% CI)4%13%9%(3, 15)26%22%(16, 28)1%11%10%(5, 16)a24%23%(17, 29)Number of subjects reporting Scalp Hair Assessment PRO score 3 at baselineN181175275151149215Scalp Hair Assessment PRO score of 0 or 1b Difference from Placebo (95% CI)5%16%11%(5, 18)33%28%(21, 34)4%16%12%(5, 19)34%30%(23, 37)\nTrial AA-1Trial AA-2\nTrial AA-1\nTrial AA-1\nTrial AA-2\nTrial AA-2\nPlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/dayPlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/day\nPlacebo\nPlacebo\nOLUMIANT2 mg/day\nOLUMIANT2 mg/day\nOLUMIANT4 mg/day\nOLUMIANT4 mg/day\nPlacebo\nPlacebo\nOLUMIANT2 mg/day\nOLUMIANT2 mg/day\nOLUMIANT4 mg/day\nOLUMIANT4 mg/day\nNumber of subjects with at least 50% scalp hair loss at baseline\nNumber of subjects with at least 50% scalp hair loss at baseline\nNumber of subjects with at least 50% scalp hair loss at baseline\nN189184281156156234\nN\nN\n189\n189\n184\n184\n281\n281\n156\n156\n156\n156\n234\n234\nSALT 20 Difference from Placebo (95% CI)5%22%16%(10, 23)35%30%(23, 36)3%17%15%(8, 22)32%30%(23, 36)\nSALT 20 Difference from Placebo (95% CI)\nSALT 20 Difference from Placebo (95% CI)\n5%\n5%\n22%16%(10, 23)\n22%16%(10, 23)\n35%30%(23, 36)\n35%30%(23, 36)\n3%\n3%\n17%15%(8, 22)\n17%15%(8, 22)\n32%30%(23, 36)\n32%30%(23, 36)\nSALT 10 Difference from Placebo (95% CI)4%13%9%(3, 15)26%22%(16, 28)1%11%10%(5, 16)a24%23%(17, 29)\nSALT 10 Difference from Placebo (95% CI)\nSALT 10 Difference from Placebo (95% CI)\n4%\n4%\n13%9%(3, 15)\n13%9%(3, 15)\n26%22%(16, 28)\n26%22%(16, 28)\n1%\n1%\n11%10%(5, 16)a\n11%10%(5, 16)a\n24%23%(17, 29)\n24%23%(17, 29)\nNumber of subjects reporting Scalp Hair Assessment PRO score 3 at baseline\nNumber of subjects reporting Scalp Hair Assessment PRO score 3 at baseline\nNumber of subjects reporting Scalp Hair Assessment PRO score 3 at baseline\nN181175275151149215\nN\nN\n181\n181\n175\n175\n275\n275\n151\n151\n149\n149\n215\n215\nScalp Hair Assessment PRO score of 0 or 1b Difference from Placebo (95% CI)5%16%11%(5, 18)33%28%(21, 34)4%16%12%(5, 19)34%30%(23, 37)\nScalp Hair Assessment PRO score of 0 or 1b Difference from Placebo (95% CI)\nScalp Hair Assessment PRO score of 0 or 1b Difference from Placebo (95% CI)\n5%\n5%\n16%11%(5, 18)\n16%11%(5, 18)\n33%28%(21, 34)\n33%28%(21, 34)\n4%\n4%\n16%12%(5, 19)\n16%12%(5, 19)\n34%30%(23, 37)\n34%30%(23, 37)\nAmong patients with substantial eyebrow and eyelash hair loss at baseline, an improvement in eyebrow and eyelash coverage was observed on OLUMIANT 4 mg once daily dosage at Week 36.\nAmong patients with substantial eyebrow and eyelash hair loss at baseline, an improvement in eyebrow and eyelash coverage was observed on OLUMIANT 4 mg once daily dosage at Week 36.\nFigure 5: Percent of Patients Achieving SALT 20\nFigure 5: Percent of Patients Achieving SALT 20\nAnalyses by age, gender, race, and body weight did not identify differences in response to 36-weeks of treatment with OLUMIANT among these subgroups. SALT 20 response rates were higher in all dose groups in patients with baseline SALT 50 to 94 versus SALT 95 to 100. See Table 15.\nAnalyses by age, gender, race, and body weight did not identify differences in response to 36-weeks of treatment with OLUMIANT among these subgroups. SALT 20 response rates were higher in all dose groups in patients with baseline SALT 50 to 94 versus SALT 95 to 100. See Table 15.\nTable 15: SALT 20 at Week 36 by Baseline SALT Severity in AATrials AA-1 and AA-2PlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/day50 % to 94% Scalp Hair Loss N SALT 201668%14733%24848%95 % to 100% Scalp Hair Loss N SALT 201781%19310%26721%\nTable 15: SALT 20 at Week 36 by Baseline SALT Severity in AA\nTable 15: SALT 20 at Week 36 by Baseline SALT Severity in AA\nTrials AA-1 and AA-2PlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/day50 % to 94% Scalp Hair Loss N SALT 201668%14733%24848%95 % to 100% Scalp Hair Loss N SALT 201781%19310%26721%\nTrials AA-1 and AA-2\nTrials AA-1 and AA-2\nTrials AA-1 and AA-2\nPlaceboOLUMIANT2 mg/dayOLUMIANT4 mg/day\nPlacebo\nPlacebo\nOLUMIANT2 mg/day\nOLUMIANT2 mg/day\nOLUMIANT4 mg/day\nOLUMIANT4 mg/day\n50 % to 94% Scalp Hair Loss N SALT 201668%14733%24848%\n50 % to 94% Scalp Hair Loss N SALT 20\n50 % to 94% Scalp Hair Loss N SALT 20\n1668%\n1668%\n14733%\n14733%\n24848%\n24848%\n95 % to 100% Scalp Hair Loss N SALT 201781%19310%26721%\n95 % to 100% Scalp Hair Loss N SALT 20\n95 % to 100% Scalp Hair Loss N SALT 20\n1781%\n1781%\n19310%\n19310%\n26721%\n26721%\nIn AA-2, patients who achieved adequate response (SALT20) to OLUMIANT 4 mg once daily at 52 weeks of treatment entered a randomized down-titration period and received OLUMIANT 2 mg once daily or remained on OLUMIANT 4 mg once daily. After an additional 24 weeks of treatment (76 weeks total), 75% (30/40) of patients randomized to OLUMIANT 2mg once daily maintained response and 98% (41/42) of patients who remained on OLUMIANT 4 mg once daily maintained response.\nIn AA-2, patients who achieved adequate response (SALT20) to OLUMIANT 4 mg once daily at 52 weeks of treatment entered a randomized down-titration period and received OLUMIANT 2 mg once daily or remained on OLUMIANT 4 mg once daily. After an additional 24 weeks of treatment (76 weeks total), 75% (30/40) of patients randomized to OLUMIANT 2mg once daily maintained response and 98% (41/42) of patients who remained on OLUMIANT 4 mg once daily maintained response.",
      "howSupplied": "16.1 How Supplied\n16.1 How Supplied\nOLUMIANT for oral administration is available as debossed, film-coated, tablets. Each tablet contains a recessed area on each face of the tablet surface.\nOLUMIANT for oral administration is available as debossed, film-coated, tablets. Each tablet contains a recessed area on each face of the tablet surface.\nOLUMIANT Tablets1 mg2 mg4 mgColorVery Light PinkLight PinkMedium PinkShapeRoundOblongRoundIdentificationLillyLillyLilly124NDC CodesBottle of 300002-4732-300002-4182-300002-4479-30\nOLUMIANT Tablets1 mg2 mg4 mgColorVery Light PinkLight PinkMedium PinkShapeRoundOblongRoundIdentificationLillyLillyLilly124NDC CodesBottle of 300002-4732-300002-4182-300002-4479-30\nOLUMIANT Tablets1 mg2 mg4 mg\nOLUMIANT Tablets\nOLUMIANT Tablets\n1 mg\n1 mg\n2 mg\n2 mg\n4 mg\n4 mg\nColorVery Light PinkLight PinkMedium Pink\nColor\nColor\nVery Light Pink\nVery Light Pink\nLight Pink\nLight Pink\nMedium Pink\nMedium Pink\nShapeRoundOblongRound\nShape\nShape\nRound\nRound\nOblong\nOblong\nRound\nRound\nIdentificationLillyLillyLilly\nIdentification\nIdentification\nLilly\nLilly\nLilly\nLilly\nLilly\nLilly\n124\n1\n1\n2\n2\n4\n4\nNDC Codes\nNDC Codes\nNDC Codes\nBottle of 300002-4732-300002-4182-300002-4479-30\nBottle of 30\nBottle of 30\n0002-4732-30\n0002-4732-30\n0002-4182-30\n0002-4182-30\n0002-4479-30\n0002-4479-30",
      "useInSpecificPopulations": "8 USE IN SPECIFIC POPULATIONS\n8 USE IN SPECIFIC POPULATIONS\n8.1 Pregnancy\n8.1 Pregnancy\nRisk Summary\nRisk Summary\nBased on the findings from animal reproduction studies, OLUMIANT may cause fetal harm during pregnancy. Available data from clinical trials and postmarketing case reports with OLUMIANT exposure in pregnancy are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no human data on chronic baricitinib exposure throughout pregnancy. There are risks to the mother and the fetus associated with rheumatoid arthritis in pregnancy (see Clinical Considerations). Consider the risks and benefits with chronic use of OLUMIANT during pregnancy.\nBased on the findings from animal reproduction studies, OLUMIANT may cause fetal harm during pregnancy. Available data from clinical trials and postmarketing case reports with OLUMIANT exposure in pregnancy are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no human data on chronic baricitinib exposure throughout pregnancy. There are risks to the mother and the fetus associated with rheumatoid arthritis in pregnancy (see Clinical Considerations). Consider the risks and benefits with chronic use of OLUMIANT during pregnancy.\nIn animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than approximately 11 and 46 times the maximum recommended human dose (MRHD) of 4 mg/day, respectively, resulted in reduced fetal body weights, increased embryolethality (rabbits only), and dose-related increases in skeletal malformations. No developmental toxicity was observed in pregnant rats and rabbits treated with oral baricitinib during organogenesis at approximately 2 and 7 times the exposure at the MRHD, respectively. In a pre- and post-natal development study in pregnant female rats, oral baricitinib administration at exposures approximately 24 times the MRHD resulted in reduction in pup viability (increased incidence of stillborn pups and early neonatal deaths), decreased fetal birth weight, reduced fetal body weight gain, decreased cytotoxic T cells on post-natal day (PND) 35 with evidence of recovery by PND 65, and developmental delays that might be attributable to decreased body weight gain. No developmental toxicity was observed at an exposure approximately 5times the exposure at the MRHD (see Data).\nIn animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than approximately 11 and 46 times the maximum recommended human dose (MRHD) of 4 mg/day, respectively, resulted in reduced fetal body weights, increased embryolethality (rabbits only), and dose-related increases in skeletal malformations. No developmental toxicity was observed in pregnant rats and rabbits treated with oral baricitinib during organogenesis at approximately 2 and 7 times the exposure at the MRHD, respectively. In a pre- and post-natal development study in pregnant female rats, oral baricitinib administration at exposures approximately 24 times the MRHD resulted in reduction in pup viability (increased incidence of stillborn pups and early neonatal deaths), decreased fetal birth weight, reduced fetal body weight gain, decreased cytotoxic T cells on post-natal day (PND) 35 with evidence of recovery by PND 65, and developmental delays that might be attributable to decreased body weight gain. No developmental toxicity was observed at an exposure approximately 5times the exposure at the MRHD (see Data).\nThe background risks of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.\nThe background risks of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.\nReport pregnancies to Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).\nReport pregnancies to Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).\nClinical Considerations\nClinical Considerations\nDisease-Associated Maternal and/or Embryo/Fetal Risk\nDisease-Associated Maternal and/or Embryo/Fetal Risk\nPublished data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.\nPublished data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.\nData\nData\nAnimal Data\nAnimal Data\nIn an embryofetal development study in pregnant rats, dosed orally during the period of organogenesis from gestation days 6 to 17, baricitinib was teratogenic (skeletal malformations that consisted of bent limb bones and rib anomalies) at exposures equal to or greater than approximately 11 times the MRHD (on an AUC basis at maternal oral doses of 10mg/kg/day and higher). No developmental toxicity was observed in rats at an exposure approximately 2times the MRHD (on an AUC basis at a maternal oral dose of 2mg/kg/day).\nIn an embryofetal development study in pregnant rats, dosed orally during the period of organogenesis from gestation days 6 to 17, baricitinib was teratogenic (skeletal malformations that consisted of bent limb bones and rib anomalies) at exposures equal to or greater than approximately 11 times the MRHD (on an AUC basis at maternal oral doses of 10mg/kg/day and higher). No developmental toxicity was observed in rats at an exposure approximately 2times the MRHD (on an AUC basis at a maternal oral dose of 2mg/kg/day).\nIn an embryofetal development study in pregnant rabbits, dosed orally during the period of organogenesis from gestation days 7 to 20, embryolethality, decreased fetal body weights, and skeletal malformations (rib anomalies) were observed in the presence of maternal toxicity at an exposure approximately 46times the MRHD (on an AUC basis at a maternal oral dose of 30mg/kg/day). Embryolethality consisted of increased post-implantation loss that was due to elevated incidences of both early and late resorptions. No developmental toxicity was observed in rabbits at an exposure approximately 7times the MRHD (on an AUC basis at a maternal oral dose of 10mg/kg/day).\nIn an embryofetal development study in pregnant rabbits, dosed orally during the period of organogenesis from gestation days 7 to 20, embryolethality, decreased fetal body weights, and skeletal malformations (rib anomalies) were observed in the presence of maternal toxicity at an exposure approximately 46times the MRHD (on an AUC basis at a maternal oral dose of 30mg/kg/day). Embryolethality consisted of increased post-implantation loss that was due to elevated incidences of both early and late resorptions. No developmental toxicity was observed in rabbits at an exposure approximately 7times the MRHD (on an AUC basis at a maternal oral dose of 10mg/kg/day).\nIn a pre- and post-natal development study in pregnant female rats dosed orally from gestation day 6 through lactation day 20, adverse findings observed in pups included decreased survival from birth to post-natal day 4 (due to increased stillbirths and early neonatal deaths), decreased birth weight, decreased body weight gain during the pre-weaning phase, increased incidence of malrotated forelimbs during the pre-weaning phase, and decreased cytotoxic Tcells on PND 35 with recovery by PND 65 at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25mg/kg/day). Developmental delays (that may be secondary to decreased body weight gain) were observed in males and females at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25mg/kg/day). These findings included decreased forelimb and hindlimb grip strengths, and delayed mean age of sexual maturity. No developmental toxicity was observed in rats at an exposure approximately 5times the MRHD (on an AUC basis at a maternal oral dose of 5mg/kg/day).\nIn a pre- and post-natal development study in pregnant female rats dosed orally from gestation day 6 through lactation day 20, adverse findings observed in pups included decreased survival from birth to post-natal day 4 (due to increased stillbirths and early neonatal deaths), decreased birth weight, decreased body weight gain during the pre-weaning phase, increased incidence of malrotated forelimbs during the pre-weaning phase, and decreased cytotoxic Tcells on PND 35 with recovery by PND 65 at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25mg/kg/day). Developmental delays (that may be secondary to decreased body weight gain) were observed in males and females at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25mg/kg/day). These findings included decreased forelimb and hindlimb grip strengths, and delayed mean age of sexual maturity. No developmental toxicity was observed in rats at an exposure approximately 5times the MRHD (on an AUC basis at a maternal oral dose of 5mg/kg/day).\n8.2 Lactation\n8.2 Lactation\nRisk Summary\nRisk Summary\nNo information is available on the presence of OLUMIANT in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Baricitinib is present in the milk of lactating rats (see Data). Because of the potential for serious adverse reactions in nursing infants advise women not to breastfeed during treatment with OLUMIANT and for 4 days after the last dose (approximately 5 to 6 elimination half-lives).\nNo information is available on the presence of OLUMIANT in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Baricitinib is present in the milk of lactating rats (see Data). Because of the potential for serious adverse reactions in nursing infants advise women not to breastfeed during treatment with OLUMIANT and for 4 days after the last dose (approximately 5 to 6 elimination half-lives).\nData\nData\nA single oral dose of 25mg/kg radiolabeled baricitinib was administered to lactating female Sprague-Dawley rats on post-partum day 13. Drug exposure was approximately 45-fold greater in milk than in plasma based on AUC0-t values.\nA single oral dose of 25mg/kg radiolabeled baricitinib was administered to lactating female Sprague-Dawley rats on post-partum day 13. Drug exposure was approximately 45-fold greater in milk than in plasma based on AUC0-t values.\n8.3 Females and Males of Reproductive Potential\n8.3 Females and Males of Reproductive Potential\nContraception\nContraception\nBased on animal studies, OLUMIANT may cause fetal harm when administered during pregnancy [see Use in Specific Populations (8.1)]. Consider pregnancy planning and prevention for females of reproductive potential.\nBased on animal studies, OLUMIANT may cause fetal harm when administered during pregnancy [see Use in Specific Populations (8.1)]. Consider pregnancy planning and prevention for females of reproductive potential.\n8.4 Pediatric Use\n8.4 Pediatric Use\nThe safety and effectiveness of OLUMIANT in pediatric patients have not been established.\nThe safety and effectiveness of OLUMIANT in pediatric patients have not been established.\n8.5 Geriatric Use\n8.5 Geriatric Use\nOf the 3100 patients treated in the rheumatoid arthritis clinical trials, a total of 537patients were 65years of age and older, including 71patients 75years of age and older. Of the 2558 patients treated in the COVID-19 clinical trials, a total of 791 were 65 years of age and older, including 295 patients 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].\nOf the 3100 patients treated in the rheumatoid arthritis clinical trials, a total of 537patients were 65years of age and older, including 71patients 75years of age and older. Of the 2558 patients treated in the COVID-19 clinical trials, a total of 791 were 65 years of age and older, including 295 patients 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].\nOf the 1200 patients in the alopecia areata clinical trials, a total of 29 patients were 65 years of age or older. The number of patients aged 65 years and older was not sufficient to determine whether they respond differently from younger patients.\nOf the 1200 patients in the alopecia areata clinical trials, a total of 29 patients were 65 years of age or older. The number of patients aged 65 years and older was not sufficient to determine whether they respond differently from younger patients.\nOLUMIANT is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.6)].\nOLUMIANT is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.6)].\n8.6 Hepatic Impairment\n8.6 Hepatic Impairment\nNo dose adjustment is necessary in patients with mild or moderate hepatic impairment.\nNo dose adjustment is necessary in patients with mild or moderate hepatic impairment.\nThe use of OLUMIANT has not been studied in patients with rheumatoid arthritis or alopecia areata and severe hepatic impairment and is therefore not recommended. OLUMIANT has not been studied in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].\nThe use of OLUMIANT has not been studied in patients with rheumatoid arthritis or alopecia areata and severe hepatic impairment and is therefore not recommended. OLUMIANT has not been studied in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].\n8.7 Renal Impairment\n8.7 Renal Impairment\nRenal function was found to significantly affect baricitinib exposure.\nRenal function was found to significantly affect baricitinib exposure.\nRheumatoid Arthritis and Alopecia Areata- The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and <60mL/min/1.73m2) should be reduced by half the recommended dose. OLUMIANT is not recommended for use in patients with rheumatoid arthritis or alopecia areata and severe renal impairment (estimated GFR of less than 30mL/min/1.73m2) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].\nRheumatoid Arthritis and Alopecia Areata- The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and <60mL/min/1.73m2) should be reduced by half the recommended dose. OLUMIANT is not recommended for use in patients with rheumatoid arthritis or alopecia areata and severe renal impairment (estimated GFR of less than 30mL/min/1.73m2) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].\nCOVID-19- The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated GFR between 30 and <60mL/min/1.732) or severe renal impairment (estimated GFR between 15 and <30mL/min/1.73 m2) is 2mg once daily and 1 mg once daily, respectively. OLUMIANT is not recommended for use in patients who are on dialysis, have end-stage renal disease (ESRD), or with estimated GFR of <15 mL/min/1.73 m2[see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].\nCOVID-19- The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated GFR between 30 and <60mL/min/1.732) or severe renal impairment (estimated GFR between 15 and <30mL/min/1.73 m2) is 2mg once daily and 1 mg once daily, respectively. OLUMIANT is not recommended for use in patients who are on dialysis, have end-stage renal disease (ESRD), or with estimated GFR of <15 mL/min/1.73 m2[see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].",
      "description": "OLUMIANT (baricitinib) is a Janus kinase (JAK) inhibitor with the chemical name {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. Baricitinib has an empirical formula of C16H17N7O2S and a molecular weight of 371.42. Baricitinib has the following structural formula:\nOLUMIANT (baricitinib) is a Janus kinase (JAK) inhibitor with the chemical name {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. Baricitinib has an empirical formula of C16H17N7O2S and a molecular weight of 371.42. Baricitinib has the following structural formula:\nOLUMIANT tablets contain a recessed area on each face of the tablet surface and are available for oral administration as debossed, film-coated tablets. The 1 mg tablet is very light pink, round, debossed with Lilly on one side and 1 on the other. The 2 mg tablet is light pink, oblong, debossed with Lilly on one side and 2 on the other. The 4 mg tablet is medium pink, round, debossed with Lilly on one side and 4 on the other.\nOLUMIANT tablets contain a recessed area on each face of the tablet surface and are available for oral administration as debossed, film-coated tablets. The 1 mg tablet is very light pink, round, debossed with Lilly on one side and 1 on the other. The 2 mg tablet is light pink, oblong, debossed with Lilly on one side and 2 on the other. The 4 mg tablet is medium pink, round, debossed with Lilly on one side and 4 on the other.\nEach tablet contains 1, 2, or 4 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.\nEach tablet contains 1, 2, or 4 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "nonclinicalToxicology": "13 NONCLINICAL TOXICOLOGY\n13 NONCLINICAL TOXICOLOGY\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\nThe carcinogenic potential of baricitinib was evaluated in Sprague-Dawley rats and Tg.rasH2 mice. No evidence of tumorigenicity was observed in male or female rats that received baricitinib for 91 to 94 weeks at oral doses up to 8 or 25mg/kg/day, respectively (approximately 7 and 30 times the MRHD on an AUC basis). No evidence of tumorigenicity was observed in Tg.rasH2 mice that received baricitinib for 26 weeks at oral doses up to 300 and 150mg/kg/day in male and female mice, respectively.\nThe carcinogenic potential of baricitinib was evaluated in Sprague-Dawley rats and Tg.rasH2 mice. No evidence of tumorigenicity was observed in male or female rats that received baricitinib for 91 to 94 weeks at oral doses up to 8 or 25mg/kg/day, respectively (approximately 7 and 30 times the MRHD on an AUC basis). No evidence of tumorigenicity was observed in Tg.rasH2 mice that received baricitinib for 26 weeks at oral doses up to 300 and 150mg/kg/day in male and female mice, respectively.\nBaricitinib tested negative in the following genotoxicity assays: the in vitro bacterial mutagenicity assay (Ames assay), in vitro chromosome aberration assay in human peripheral blood lymphocytes, and in vivo rat bone marrow micronucleus assay.\nBaricitinib tested negative in the following genotoxicity assays: the in vitro bacterial mutagenicity assay (Ames assay), in vitro chromosome aberration assay in human peripheral blood lymphocytes, and in vivo rat bone marrow micronucleus assay.\nFertility (achievement of pregnancy) was reduced in male and female rats that received baricitinib at oral doses of 50 and 100mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis) based upon findings that 7 of 19 (36.8%) drug-treated females with evidence of mating were not gravid compared to 1 of 19 (5.3%) control females. It could not be determined from the study design if these findings were attributable to toxicities in one sex or both. Fertility was unaffected in male and female rats at oral doses of 15mg/kg and 25mg/kg, respectively (approximately 13 and 26 times the MRHD on an AUC basis). However, maintenance of pregnancy was adversely affected at these doses based upon findings of increased post-implantation losses (early resorptions) and decreased numbers of mean viable embryos per litter. The number of viable embryos was unaffected in female rats that received baricitinib at an oral dose of 5mg/kg/day and were mated to males that received the same dose (approximately 6 times the MRHD on an AUC basis). Reproductive performance was unaffected in male and female rats that received baricitinib at oral doses up to 50 and 100mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis).\nFertility (achievement of pregnancy) was reduced in male and female rats that received baricitinib at oral doses of 50 and 100mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis) based upon findings that 7 of 19 (36.8%) drug-treated females with evidence of mating were not gravid compared to 1 of 19 (5.3%) control females. It could not be determined from the study design if these findings were attributable to toxicities in one sex or both. Fertility was unaffected in male and female rats at oral doses of 15mg/kg and 25mg/kg, respectively (approximately 13 and 26 times the MRHD on an AUC basis). However, maintenance of pregnancy was adversely affected at these doses based upon findings of increased post-implantation losses (early resorptions) and decreased numbers of mean viable embryos per litter. The number of viable embryos was unaffected in female rats that received baricitinib at an oral dose of 5mg/kg/day and were mated to males that received the same dose (approximately 6 times the MRHD on an AUC basis). Reproductive performance was unaffected in male and female rats that received baricitinib at oral doses up to 50 and 100mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis).",
      "mechanismOfAction": "12.1 Mechanism of Action\n12.1 Mechanism of Action\nBaricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.\nBaricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.\nJAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.\nJAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.",
      "contraindications": "None.\nNone.",
      "highlights": {
        "dosageAndAdministration": "Administration Instructions:\nAdministration Instructions:\nSee the full prescribing information for recommended evaluations and immunizations prior to treatment. (2.1)Rheumatoid Arthritis and Alopecia Areata: Avoid initiation or interrupt OLUMIANT in patients with anemia (hemoglobin <8g/dL), lymphopenia (ALC<500cells/mm3) or neutropenia (ANC<1000cells/mm3). (2.1, 2.5, 5.8)COVID-19: Avoid initiation or interrupt OLUMIANT in patients with lymphopenia (ALC<200 cells/mm3) or neutropenia (ANC<500cells/mm3). (2.1, 2.5, 5.8)\nSee the full prescribing information for recommended evaluations and immunizations prior to treatment. (2.1)\nSee the full prescribing information for recommended evaluations and immunizations prior to treatment. (2.1)\nRheumatoid Arthritis and Alopecia Areata: Avoid initiation or interrupt OLUMIANT in patients with anemia (hemoglobin <8g/dL), lymphopenia (ALC<500cells/mm3) or neutropenia (ANC<1000cells/mm3). (2.1, 2.5, 5.8)\nRheumatoid Arthritis and Alopecia Areata: Avoid initiation or interrupt OLUMIANT in patients with anemia (hemoglobin <8g/dL), lymphopenia (ALC<500cells/mm3) or neutropenia (ANC<1000cells/mm3). (2.1, 2.5, 5.8)\nCOVID-19: Avoid initiation or interrupt OLUMIANT in patients with lymphopenia (ALC<200 cells/mm3) or neutropenia (ANC<500cells/mm3). (2.1, 2.5, 5.8)\nCOVID-19: Avoid initiation or interrupt OLUMIANT in patients with lymphopenia (ALC<200 cells/mm3) or neutropenia (ANC<500cells/mm3). (2.1, 2.5, 5.8)\nRecommended Dosage:\nRecommended Dosage:\nRheumatoid Arthritis:\nRheumatoid Arthritis:\n2mg once daily. (2.2)OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. (2.2)\n2mg once daily. (2.2)\n2mg once daily. (2.2)\nOLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. (2.2)\nOLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. (2.2)\nCOVID-19:\nCOVID-19:\n4 mg once daily for up to 14 days. (2.3)\n4 mg once daily for up to 14 days. (2.3)\n4 mg once daily for up to 14 days. (2.3)\nAlopecia Areata:\nAlopecia Areata:\n2mg once daily. Increase to 4 mg once daily, if the response to treatment is not adequate. (2.4)For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4mg once daily. (2.4)Reduce the dose to 2mg once daily when an adequate response has been achieved. (2.4)\n2mg once daily. Increase to 4 mg once daily, if the response to treatment is not adequate. (2.4)\n2mg once daily. Increase to 4 mg once daily, if the response to treatment is not adequate. (2.4)\nFor patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4mg once daily. (2.4)\nFor patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4mg once daily. (2.4)\nReduce the dose to 2mg once daily when an adequate response has been achieved. (2.4)\nReduce the dose to 2mg once daily when an adequate response has been achieved. (2.4)\nDosage Modifications in Patients with Renal or Hepatic Impairment, or Cytopenias\nDosage Modifications in Patients with Renal or Hepatic Impairment, or Cytopenias\nSee the full prescribing information for dosage modifications by indication. (2.5, 2.6, 5.8)\nSee the full prescribing information for dosage modifications by indication. (2.5, 2.6, 5.8)\nSee the full prescribing information for dosage modifications by indication. (2.5, 2.6, 5.8)"
      }
    },
    "metaDescription": "<p>OLUMIANT is a JAK inhibitor with formula C16H17N7O2S, weight 371.42. Tablets: 1 mg (light pink, round), 2 mg (light pink, oblong), 4 mg (medium pink, round).</p>",
    "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>Rheumatoid Arthritis: Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.</li>\n<li>Coronavirus Disease 2019 (COVID-19): Treatment of hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</li>\n<li>Alopecia Areata: Treatment of adult patients with severe alopecia areata.</li>\n</ul>",
    "contraIndications": "<p>No contraindications</p>",
    "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Serious infections, including bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens, have been reported. Avoid use in patients with active, serious infections.</li>\n<li>Evaluate patients for active tuberculosis (TB) before administration. Do not give OLUMIANT to patients with active TB. Monitor for signs and symptoms of TB during use.</li>\n<li>Viral reactivation, including herpes zoster, has been reported. Interrupt treatment if herpes zoster develops.</li>\n<li>Consider risks and benefits in patients with a history of malignancy, particularly in current or past smokers.</li>\n<li>Monitor for major adverse cardiovascular events (MACE) in patients with cardiovascular risk factors. Discontinue in patients who experience myocardial infarction or stroke.</li>\n<li>Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed. Avoid use in patients at increased risk of thrombosis.</li>\n<li>Hypersensitivity reactions, such as angioedema and urticaria, have been observed. Discontinue if serious hypersensitivity occurs.</li>\n<li>Gastrointestinal perforations have been reported. Monitor patients at increased risk, such as those with a history of diverticulitis.</li>\n<li>Laboratory abnormalities include neutropenia, lymphopenia, anemia, liver enzyme elevations, and lipid elevations. Monitor and adjust dosing based on laboratory results.</li>\n<li>Avoid use of live vaccines with OLUMIANT. Update immunizations prior to initiating therapy.</li>\n</ul>",
    "dosing": "<p><h3>Adult Dosing</h3></p>\n<ul>\n<li>Rheumatoid Arthritis: 2 mg once daily orally, with or without food. May be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.</li>\n<li>COVID-19: 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.</li>\n<li>Alopecia Areata: 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response is not adequate. For patients with nearly complete or complete scalp hair loss, consider 4 mg once daily. Once an adequate response is achieved, decrease to 2 mg once daily.</li>\n</ul>\n\n<p><h3>Dosage Modifications Due to Infections, Cytopenias, and Anemia</h3></p>\n<ul>\n<li>Rheumatoid Arthritis and Alopecia Areata: Avoid use in patients with active, serious, or opportunistic infections. Hold treatment if a serious infection develops until controlled.</li>\n<li>COVID-19: Monitor for new infections. Consider risks and benefits in patients with concurrent infections.</li>\n</ul>\n\n<p><h3>Dosage Modifications for Cytopenias and Anemia</h3></p>\n<ul>\n<li>Rheumatoid Arthritis and Alopecia Areata:\n  <ul>\n    <li>ALC < 500 cells/L: Interrupt until ALC ≥ 500 cells/L.</li>\n    <li>ANC < 1000 cells/L: Interrupt until ANC ≥ 1000 cells/L.</li>\n    <li>Hemoglobin < 8 g/dL: Interrupt until hemoglobin ≥ 8 g/dL.</li>\n  </ul>\n</li>\n<li>COVID-19:\n  <ul>\n    <li>ALC < 200 cells/L: Interrupt until ALC ≥ 200 cells/L.</li>\n    <li>ANC < 500 cells/L: Interrupt until ANC ≥ 500 cells/L.</li>\n  </ul>\n</li>\n</ul>\n\n<p><h3>Dosage Modifications for Renal Impairment</h3></p>\n<ul>\n<li>Rheumatoid Arthritis:\n  <ul>\n    <li>Mild (eGFR 60-<90 mL/min/1.73 m²): 2 mg once daily.</li>\n    <li>Moderate (eGFR 30-<60 mL/min/1.73 m²): 1 mg once daily.</li>\n    <li>Severe (eGFR <30 mL/min/1.73 m²): Not recommended.</li>\n  </ul>\n</li>\n<li>COVID-19:\n  <ul>\n    <li>Mild (eGFR 60-<90 mL/min/1.73 m²): 4 mg once daily.</li>\n    <li>Moderate (eGFR 30-<60 mL/min/1.73 m²): 2 mg once daily.</li>\n    <li>Severe (eGFR 15-<30 mL/min/1.73 m²): 1 mg once daily.</li>\n    <li>End Stage Renal Disease or Acute Kidney Injury (e"
  }
]